

Heart failure and obesity: Translational approaches and therapeutic perspectives.

A scientific statement of the Heart Failure Association of the ESC

Gianluigi Savarese^{1*}, **Gabriele G. Schiattarella^{2,3,4,5†}**, **Felix Lindberg¹**, **Markus S. Anker⁶**, **Antoni Bayes-Genis⁷**, **Magnus Bäck^{8,9}**, **Frieder Braunschweig¹⁰**, **Chiara Bucciarelli-Ducci^{11,12}**, **Javed Butler^{13,14}**, **Antonio Cannata^{15,16}**, **Federico Capone^{2,3,4,17,18}**, **Ovidiu Chioncel¹⁹**, **Emilia D'Elia^{20,21}**, **Arantxa González^{22,23}**, **Gerasimos Filippatos²⁴**, **Nicolas Girerd⁸**, **Jean-Sébastien Hulot^{25,26}**, **Carolyn S.P. Lam²⁷**, **Lars H. Lund⁹**, **Christoph Maack^{28,29}**, **Brenda Moura^{30,31}**, **Mark C. Petrie³²**, **Massimo Piepoli^{33,34}**, **Abdullah Shehab³⁵**, **Mehmet B. Yilmaz³⁶**, **Peter Seferovic^{37,38}**, **Carlo G. Tocchetti³⁹**, **Giuseppe M.C. Rosano^{40,41}**, and **Marco Metra^{42,43}**

¹Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; ²Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC), Deutsches Herzzentrum der Charité (DHZC), Charité – Universitätsmedizin Berlin, Berlin, Germany; ³DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; ⁴Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; ⁵Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy; ⁶Department of Cardiology CBF German Heart Center Charité, DZHK, BCRT, University Medicine Berlin FU and HU, Berlin, Germany; ⁷Heart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV, Badalona, Spain; ⁸Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France; ⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; ¹⁰Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; ¹¹Royal Brompton and Harefield Hospitals, Guys' and St Thomas NHS Trust, London, UK; ¹²School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College University, London, UK; ¹³Baylor Scott and White Research Institute, Dallas, TX, USA; ¹⁴University of Mississippi, Jackson, MS, USA; ¹⁵British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK; ¹⁶Cardiology Department, King's College Hospital NHS Foundation Trust, London, UK; ¹⁷Unit of Internal Medicine III, Department of Medicine (DIMED), Padua University Hospital, University of Padua, Padova, Italy; ¹⁸Department of Biomedical Sciences, University of Padua, Padova, Italy; ¹⁹Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine Carol Davila, Bucharest, Romania; ²⁰Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy; ²¹School of Medicine and Surgery, University Milano-Bicocca, Milan, Italy; ²²Program of Cardiovascular Diseases, CIMA Universidad de Navarra, Department of Cardiology and Cardiac Surgery, Clínica Universidad de Navarra and IdiSNA, Pamplona, Spain; ²³CIBERCV, Carlos III Institute of Health, Madrid, Spain; ²⁴Department of Cardiology, University Hospital Attikon, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; ²⁵Université Paris Cité, INSERM, PARCC, Paris, France; ²⁶CIC1418 and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France; ²⁷National Heart Centre Singapore & Duke-National University of Singapore, Singapore; ²⁸Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany; ²⁹Medical Clinic 1, University Clinic Würzburg, Würzburg, Germany; ³⁰Department of Cardiology, Armed Forces Hospital, Porto, Portugal; ³¹Faculty of Medicine, University of Porto, Porto, Portugal; ³²School of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; ³³University Cardiology, IRCCS Policlinico San Donato, Milan, Italy; ³⁴Department of Preventive Cardiology, Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland; ³⁵Department of Cardiology, Royal Burjeel Hospital, UAE University, Al Ain, UAE; ³⁶Department of Cardiology, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey; ³⁷Faculty of Medicine, University of Belgrade, and Serbian Academy of Sciences and Arts, Belgrade, Serbia; ³⁸University of Belgrade, Belgrade, Serbia; ³⁹Cardio-Oncology Unit, Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy; ⁴⁰Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy;

*Corresponding author. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, 118 83 Stockholm, Sweden.
 Email: gianluigi.savarese@ki.se

[Correction added on 12 June 2025, after first online publication: Massimo Piepoli's affiliations have been corrected in this version.]

†Contributed equally as co-first authors.

⁴¹Cardiology, San Raffaele Cassino Hospital, Cassino, Italy; ⁴²Cardiology and Cardiac Catheterization Laboratory, Cardio-Thoracic Department, Civil Hospitals, Brescia, Italy; and ⁴³Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Received 11 December 2024; revised 2 April 2025; accepted 8 April 2025; online publish-ahead-of-print 6 May 2025

Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few years, new evidence on the mechanisms linking obesity with HF has been reported, particularly in relation to HF with preserved ejection fraction. Novel therapies inducing weight loss appear to have favourable effects on health status and cardiovascular risk. Against the backdrop of this rapidly evolving evidence landscape, HF clinicians are increasingly required to tailor their preventive, diagnostic, and therapeutic approaches to HF in the presence of obesity. This scientific statement by the Heart Failure Association of the European Society of Cardiology provides an up-to-date summary on obesity in HF, covering key areas such as epidemiology, translational aspects, diagnostic challenges, therapeutic approaches, and trial design.

Keywords

Obesity • Heart failure • Risk factors • HFReEF • HFPeEF

Preamble

The prevalence of obesity is increasing dramatically, having reached pandemic proportions. In 2022, 43% of adults were overweight and 16% lived with obesity worldwide.¹ Obesity carries a high risk of cardiovascular diseases, especially heart failure (HF), both directly and indirectly through its association with other cardiovascular risk factors, including diabetes, sleep apnoea, hypertension, and dyslipidaemia. It often mimics symptoms and signs characterizing HF, for example fatigue, dyspnoea, and oedema, and can make diagnosis of HF challenging. Over the past few years, several novel therapeutic options specifically targeting obesity have become available, and many more are currently under development. Therefore, obesity warrants special consideration throughout all the steps of HF management, from prevention and diagnosis to treatment and drug development. This scientific statement by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) aims to provide a framework for approaching HF diagnosis, treatment, and trial design in the context of the obesity pandemic.


Overweight and obesity: definitions and diagnosis

Obesity is characterized by excessive adiposity, with or without abnormal distribution or function of the adipose tissue.² In individuals with pre-clinical obesity, function of other tissues and organs is preserved, whereas there is predisposition to clinical obesity as well as, among other diseases, cardiovascular disease.² Conversely, clinical obesity is characterized by alterations in the function of tissues and organs due to excessive and/or abnormal adiposity.²

Excess adiposity is commonly estimated by the body mass index [BMI = body weight (kg)/height² (m²)].³ BMI is not a direct measure of adiposity but rather correlates with the percentage of body fat, and this relationship is independently influenced by sex, age, and ethnicity.^{3–5} In adults (aged 18 years and over), obesity is defined by

a BMI ≥ 30 kg/m² and overweight (also called pre-obesity) by a BMI between 25 and 30 kg/m².³ These cut-offs are internationally recognized as they are associated with health outcomes, cardiovascular risk, and mortality.^{6,7} However, the optimal thresholds for defining obesity may differ by ethnicity. For example, in the Asian population, obesity is classified at a lower BMI (≥ 25 kg/m²), with overweight defined as a BMI between 23 and 25 kg/m².^{8,9} Patients with higher BMI also exhibit a higher prevalence of other cardiovascular comorbidities, such as type 2 diabetes mellitus (T2DM) and arterial hypertension.^{10,11}

Body mass index is easy to measure in everyday practice, but body weight can be affected by non-fat related mechanisms such as fluid retention in patients with HF. In addition, BMI does not distinguish between muscle and adipose mass, nor general and visceral adiposity. A larger abdominal or trunk fat content (also known as visceral, android, or central obesity) has been associated with an increased risk of metabolic syndrome, T2DM, high blood pressure, and heart disease,^{3,12,13} with a stronger association than for BMI.¹⁴ Central obesity is commonly assessed by measuring the waist-to-hip ratio or waist-to-height ratio, but it can also be more easily estimated by a single waist circumference (WC) measurement taken at the level of the midway horizontal distance between the lowest rib and the superior iliac crest (with cut-offs of 94 cm in European men and 80 cm in non-pregnant European women).³ While there is a strong correlation between overall obesity and central obesity, some individuals may have abdominal obesity in the absence of overall obesity based on BMI (also known as normal-weight obesity), leading to an underestimation of the cardiovascular risk.¹² Conversely, some obese patients as defined by BMI may have limited abdominal and visceral obesity. Central obesity is best assessed by imaging techniques, such as dual-energy X-ray absorptiometry (DEXA) or magnetic resonance imaging (MRI), which are, however, often not easily accessible in daily practice. As a result, combining BMI and waist-to-height ratio is recommended over BMI alone to better detect fat accumulation in the body and to better assess cardiovascular risk.^{3,15,16}



In addition, some adipose tissue-dependent metabolic derangements can have a negative impact on skeletal muscle and can lead to progressive loss of muscle mass and function or sarcopenia. The co-existence of obesity and sarcopenia defines sarcopenic obesity,¹⁷ a condition associated with worse clinical outcomes including patients with HF.^{18,19} Both sarcopenia and obesity are well documented as separate entities in patients with HF, but their combination is poorly investigated. The assessment of skeletal muscle functional parameters (e.g. handgrip strength, or chair stand test) is, thus, also useful in patients with obesity and HF.

Epidemiology of obesity in relation to heart failure

Prevalence of obesity

The World Health Organization reports tripled obesity prevalence since 1975, expressing concern about the subsequent rise in HF.²⁰ The prevalence of obesity varies geographically due to differences in diet, lifestyle, genetic factors, and healthcare access. Most recent statistics highlight a prevalence of ~17% in Europe (2019), 30–35% in North America (2022), ~25% in Latin America (2016), ~13% in Africa (2016), ~30% in Australia (2017–2018), 20–40% in Middle East (2018), from ~5% in Japan to ~20% in Malaysia (2019) in Asia, with large geographical variations. By 2025 worldwide prevalence of obesity is expected to reach 25%.^{1,21–24}

Obesity and heart failure risk

Obesity increases the risk of HF by two-six-fold regardless of sex,²⁵ with a stronger adjusted (for age, sex, ethnicity, income, education, and physical activity) association with incident HF with preserved

ejection fraction (HFpEF) than incident HF with reduced ejection fraction (HFrEF)²⁶ (Figure 1). The differential association between BMI and HFpEF versus HFrEF has been reported to be more pronounced in women than men.^{27,28} Consistently, prevalence of obesity in HF is overall high (~35% in the Global Congestive Heart Failure registry across 40 countries with different economic levels regardless of ejection fraction [EF]),²⁹ and higher in HFpEF versus HF with mildly reduced EF (HFmrEF) versus HFrEF, that is ~40% in CHAMP-HF (US) and ~30% in Get With The Guidelines-HF (US),^{30,31} ~25% in the Swedish HF (SwedeHF) registry and in the TITRATE-HF study (The Netherlands) in HFrEF,^{32,33} 28% and 31% in HFmrEF and HFpEF in SwedeHF,³² respectively, 45% in the EMPEROR-Preserved and DELIVER trials enrolling patients with HFmrEF/HFpEF.^{34,35}

Obesity and heart failure prognosis

Patients with HF and obesity according to the BMI criteria have sometimes been reported to have better prognosis compared with those with lower BMI in different settings, that is chronic and advanced HF, HFpEF and HFrEF.^{36,37} In the MAGGIC meta-analysis, the relationship between BMI and mortality was U-shaped regardless of EF, with a nadir at BMI at 30–34.9 kg/m².³⁶ However, this 'obesity paradox', that is the apparent lower risk in patients with HF who are overweight/obese (vs. normal weight), has been questioned by more recent studies. When in the ASIAN-HF registry obesity was defined according to the waist-to-height ratio (≥ 0.55), obesity was rather associated with increased risk of HF hospitalization or mortality, which was consistent with findings from the TOPCAT in HFpEF and only in women in the BIOSTAT-CHF, suggesting that measures of adiposity, such as waist-to-height ratio, could better reflect body composition than BMI.^{38–40} In patients with HFrEF in the PARADIGM-HF, the 'obesity paradox' of BMI was

Compared with lean patients with HFpEF, in those with obesity the adaptive decrease in pulmonary vascular resistance during exercise is absent and thereby the increase in mean pulmonary artery pressure steeper, resulting in higher oxygen consumption per myocardial work (i.e. decreased myocardial efficacy).⁵⁵ Accordingly, patients with obesity who experience dyspnoea on exertion tend to exhibit poorer performance on functional tests like the 6-min walk test, highlighting the impact of obesity on physical capacity and cardiovascular health.⁶⁵

Beyond the direct effects of body weight and adiposity on alterations in cardiac structure and function, its association with hypertension, T2DM, AF and ischaemic heart disease, further exacerbates the risk of HF, and also indirectly links obesity with HFrEF.

Even if obesity is more frequently associated with HFpEF, higher BMI determines an increased risk also of HFrEF, especially in men.²⁷ Excessive adiposity promotes coronary atherosclerosis progression and incident myocardial infarction which is the most common underlying aetiology in HFrEF and HFmrEF.^{66–68} While obesity-driven HFpEF is primarily a consequence of metabolic dysfunction, systemic inflammation, and microvascular disease, in ischaemic HFrEF visceral adiposity accelerates atherosclerosis, contributes to plaque instability, and increases infarct size, leading to progressive systolic dysfunction.

Obesity-induced structural and functional cardiac changes, including left atrial enlargement, increased epicardial fat, and systemic inflammation, contribute to atrial remodelling and increased AF susceptibility, which in turn might lead to HF or worsen outcomes in patients with HF.^{69,70} Haemodynamic alterations, such as increased cardiac output and preload, further exacerbate atrial stretch and AF risk.^{71–73} The presence of obesity also complicates the clinical assessment of AF beyond HF, as symptoms, for example fatigue, dyspnoea, etc., may be attributed to excess weight rather than AF/HF-related haemodynamic compromise. Obesity is also associated with increased AF recurrence, with AF burden associated with worse outcome in HF patients.^{74,75} N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are higher in patients with AF,⁷⁶ due to the atrial stretch and subsequent peptide release occurring during the chaotic atrial depolarization. Levels of natriuretic peptides are reduced in obesity (see below), thus the opposite effects of AF and increased adiposity should be considered when using NT-proBNP as diagnostic biomarker in the HF setting.

Molecular aspects of cardiometabolic heart failure with preserved ejection fraction and obesity


Heart failure with preserved EF is a complex syndrome. In the most common phenotype, known as cardiometabolic HFpEF, obesity is a major driver of cardiac dysfunction. Excessive adiposity promotes several derangements, but the effects of obesity and metabolic syndrome on cardiac metabolism are pivotal in HFpEF

progression.⁷⁷ Cardiac energetics rely on the intricate interplay of various energy substrates, including fatty acids (FAs), ketone bodies (KBs), and glucose. In cardiometabolic HFpEF, the heart exhibits a distinct pattern of substrate utilization with significant changes in the balance between FAs, KBs, and glucose utilization (Figure 3).

Fatty acids, composed of an aliphatic chain and a carboxyl group, provide high energy yield upon oxidation. Long-chain fatty acids (LCFAs) are the predominant fuel for the healthy adult heart, given its high energy demand.⁷⁸ LCFA oxidation generates significant adenosine triphosphate (ATP) but requires substantial oxygen. In HFrEF, LCFAs metabolism is defective and an increase in alternative substrate oxidation is observed.⁷⁹ In cardiometabolic HFpEF, LCFAs overload in the myocardium and insulin resistance together contribute to a high reliance on FA oxidation compared with other substrates,⁸⁰ despite overall ATP production being defective.⁸¹

Long-chain FAs are primarily consumed as triglycerides and other esters, hydrolyzed with digestion, and transported to tissues where they are re-esterified or oxidized.⁸² Pathologically high levels of LCFAs can lead to lipid overload and lipotoxicity, characterized by myocardial steatosis and diastolic dysfunction. Lipotoxicity involves increased reactive oxygen species production, primarily driven by intermediates like diacylglycerol and ceramides,⁸³ contributing to cardiomyocyte apoptosis and mitochondrial dysfunction. Beyond intracellular lipid accumulation, ectopic fat depots—epicardial, pericardial, and perivascular adipose tissue—play a crucial role in cardiovascular dysfunction. Epicardial adipose tissue surrounding the myocardium is highly metabolically active and secretes inflammatory cytokines and adipokines such as tumour necrosis factor- α , interleukin-6, and leptin, promoting myocardial fibrosis, oxidative stress, and microvascular dysfunction.^{84–86} Excessive epicardial adipose tissue is linked to increased LV filling pressures, impaired relaxation, and worsened diastolic function.^{87,88} Similarly, pericardial and perivascular fat depots contribute to coronary microvascular dysfunction and vascular inflammation by releasing vasoconstrictive and pro-atherogenic mediators, impairing endothelial function, increasing arterial stiffness, and exacerbating HFpEF pathophysiology. LCFAs also impact inflammation and epigenetic modulation, particularly through macrophage polarization and DNA methylation. Saturated FAs promote pro-inflammatory M1 macrophages via upregulation of DNA methyltransferases,⁸⁹ while polyunsaturated fatty acids (PUFAs) exhibit protective roles. For instance, n-3 PUFAs can modulate leptin expression and DNA methylation, thereby reducing the onset of diastolic dysfunction.⁹⁰

Short-chain FAs (SCFAs), such as acetate, propionate, and butyrate, derive from gut microbiota fermentation and have beneficial effects in metabolic cardiomyopathy. Unlike LCFAs, SCFAs do not rely on the carnitine shuttle for mitochondrial entry, making them advantageous under conditions where FA oxidation is impaired.^{91,92} SCFAs act as signalling molecules through G protein-coupled receptors,^{93,94} influencing blood pressure, inflammation, and metabolic homeostasis.⁹⁵ They inhibit histone deacetylases, leading to anti-inflammatory effects and reduced lipid absorption, which can mitigate obesity and insulin resistance.^{96,97}



Glucose serves as a crucial energy substrate for the heart, especially under ischemic conditions due to its lower oxygen requirement for ATP production. In HFpEF, insulin signalling is impaired and glucose oxidation is blunted,^{80,98} highlighting the importance of substrate competition (Randle cycle) in metabolic adaptation.⁹⁹ KBs, primarily acetoacetate and β -hydroxybutyrate, are produced by the liver from FAs and serve as alternative energy sources during fasting or prolonged exercise. KB metabolism involves adipose tissue, liver, and peripheral tissues like the heart. Elevated FAs stimulate ketogenesis, providing an energy source during reduced glucose availability.¹⁰⁰ KBs play a role in cellular signalling and epigenetic regulation, and an increased use of KBs for energy is considered to be an adaptive response in patients with HFpEF.¹⁰¹ However, in obese patients with HFpEF, studies suggest a decreased reliance on KBs for energy.⁸⁰ This shift in energy metabolism could contribute to the unique pathophysiology of HFpEF.

Acetylation, a reversible post-translational modification, impacts numerous proteins including histones, cytosolic proteins, and key mitochondrial enzymes, and can occur enzymatically or non-enzymatically, regulated by acetyl-CoA availability. Histone acetyltransferases and histone deacetylases transfer and remove acetyl groups, respectively, but these enzymes, now often referred to as lysine acetyltransferases and lysine deacetylases, highlight the importance of lysine residues in this modification.¹⁰² Acetylation affects protein function, stability, and interactions, influencing cellular metabolism and disease progression, particularly in cardiometabolic conditions like HFpEF.¹⁰³

In summary, in patients with obesity and HFpEF, cardiac metabolic remodelling alters the delicate balance between FAs, glucose, and KBs. LCFAs are primary fuels, but their pathological accumulation leads to lipotoxicity and diastolic dysfunction. A lower dietary fibre intake weakens the protective effects of SCFAs. Glucose utilization is defective and KB oxidation, usually providing an alternative energy source, is not increased in cardiometabolic

HFpEF.⁸⁰ Additionally, ectopic fat depots act as key mediators of myocardial and vascular dysfunction, amplifying inflammatory signalling, worsening diastolic compliance, and contributing to the adverse haemodynamic profile characterizing HFpEF. Understanding these molecular aspects is essential for developing targeted therapies to manage HFpEF and its cardiometabolic phenotype associated with obesity.

Diagnostic considerations in subjects with heart failure and obesity

The diagnosis of HF in patients with obesity is challenging, due to partial overlap in symptoms and signs, such as dyspnoea and oedema. Distinguishing, among obese people, those with dyspnoea due to HF from those with non-cardiac dyspnoea, is critical. Characteristics clearly identifying dyspnoea as cardiogenic are (1) its causal relationship with lung congestion, (2) concomitant increase in cardiac filling pressures, at rest and during exercise. Therefore, especially when NT-proBNP levels are low as in obese individuals (see below), the assessment of congestion represents a key component of the diagnostic algorithm for HF. Further, there are specific issues in need to be considered when interpreting biomarker profiles and imaging tests.

Biomarkers

Natriuretic peptides

Body mass index is inversely correlated with natriuretic peptides, and obesity can therefore confound the assessment of natriuretic peptides in HF. However, in patients with HF, bariatric surgery (which induces significant weight loss) appears to increase natriuretic peptide levels despite being associated with improved cardiac function.^{104,105}

Patients with HF and obesity have lower levels of plasma B-type natriuretic peptide (BNP) compared with those without obesity, and there is an inverse correlation between plasma BNP levels and BMI,¹⁰⁶ due to the high expression of natriuretic peptide receptor (NPR)-A and NPR-C in adipocytes,¹⁰⁷ and therefore the higher uptake of BNP by adipocytes and lower levels in the bloodstream. Obese patients with HF who do have elevated BNP (>35 pg/ml) are more likely to have right ventricular remodelling and elevated pulmonary artery pressure.¹⁰⁸

Furthermore, NT-proBNP, which does not bind to NPR-A and NPR-C, is also found to be lower in obese patients, indicating that different mechanisms are involved. Indeed, in the context of HF with obesity, BNP production and secretion decrease as insulin resistance increases.¹⁰⁹ Additionally, increased levels of Thr71-glycosylated proBNP impair proBNP processing, leading to decreased levels of NT-proBNP and BNP.¹¹⁰ Therefore, reduced BNP production, alterations in peripheral fat cell metabolism, and impaired proBNP processing are all mechanisms that together contribute to the decrease in plasma BNP/NT-proBNP levels in obese patients with HF,¹¹¹ challenging their assessment for diagnostic and prognostic purposes.

As a result, it has been suggested that lower NT-proBNP cut-off values should be used for ruling out HF in individuals with obesity. In a recent analysis, including multiple cohorts of HFpEF patients where diagnosis of cardiac dyspnoea was conclusively determined by exercise catheterization, a cut-off of 50 pg/ml has been proposed to reduce false negatives in outpatients with BMI ≥ 35 kg/m².¹¹²

Adipokines and other biomarkers

A number of adipokines and growth factors produced by the adipose tissue have been shown to be associated with increased cardiovascular risk including leptin, adiponectin, omentin, visfatin or apelin among others.¹¹³ Leptin plays a key role on energy metabolism and homeostasis, neuroendocrine regulation and inflammation.¹¹⁴ The leptin–aldosterone–neprilysin axis is involved in the development of cardiac inflammation and fibrosis across the spectrum of HF in patients with obesity.¹¹⁵ In patients with HF and metabolic syndrome, circulating leptin was the most significantly elevated biomarker from a panel of 363 biomarkers.¹¹⁶ On the other hand, adiponectin is an anti-inflammatory, anti-fibrotic and cardioprotective adipokine.¹¹⁴ Leptin and adiponectin are regulated in an opposite manner, with obese individuals presenting high circulating levels of leptin but lower levels of adiponectin. Paradoxically, adiponectin levels increase during HF progression and are associated with adverse outcomes,^{117,118} but this is probably due to the effect of wasting (i.e. unintentional loss of body mass during HF progression) that occurs during later HF stages and correlate with increased adiponectin levels. Therefore, higher levels of both these biomarkers might be indicative of HF in patients with obesity. Resistin is another adipokine secreted by the adipose tissue, that impairs glucose homeostasis.¹¹⁹ Circulating plasma levels of both leptin and resistin are increased in patients with HF, and those patients with lower plasma leptin and resistin levels showed a greater improvement in EF and a decrease in NT-proBNP during follow-up,¹²⁰ suggesting a potential prognostic role for these biomarkers in the obese HF setting.

Fibroblast growth factor-21 (FGF-21) is expressed by the adipose tissue and by other organs such as skeletal muscle, liver or pancreas, it is involved in thermogenesis, and induces adiponectin secretion.¹²¹ It is elevated in patients with obesity and metabolic syndrome,¹²² and this paradoxical increase is thought to be related to a resistant state.¹²³ Elevated circulating levels of FGF-21 have been found to be associated with cardiovascular risk.^{119,124} However, as circulating FGF-21 mainly has origin in the liver, its relevance in the obesity–HF axis needs to be further elucidated.¹²⁵ Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that plays a role in regulating energy balance and is elevated in patients with HFpEF or HFpEF and particularly acute HF.¹²⁶ Elevated GDF-15 in patients with HF predicts risk of HF hospitalizations or mortality.¹²⁷ Although GDF-15 is linked with cachexia and is most elevated in underweight patients, those with HF and obesity had higher GDF-15 levels than normal weight patients in the SUPPORT trial.¹²⁷

Inflammatory biomarkers are also correlated with obesity and adiposity measures. Interleukin-6 concentrations are elevated in HF and are associated with increased total body and trunk fat mass, as well as with poorer exercise capacity and symptoms in patients with HFpEF.¹²⁸ C-reactive protein (CRP) is highly positively associated with measures of adiposity such as BMI, WC, and waist-to-hip ratio.^{129,130} Weight loss interventions, either lifestyle changes or surgical, were associated with significant decrease in CRP levels.¹³¹ In recent clinical trials, semaglutide reduced CRP concentration irrespective of baseline BMI or glycemic status.¹³²

Adiposity measures

Heart failure has been shown to rank second among the cardiovascular diagnoses most strongly associated with BMI, and is also linked to other anthropometric measures like WC and waist-to-hip ratio.¹³³ However, measures of body composition by means of bioelectrical impedance analysis show a significant association of fat mass, but not fat-free mass index, with HF,¹³³ indicating that body composition measures may refine risk stratification for HF in individuals with obesity, as supported by the obesity paradox being observed when measures of body mass but not of body composition were applied.¹³⁴ Body composition and regional adiposity distribution measured by DEXA,¹³⁵ computed tomography (CT),¹³⁶ or MRI,¹³⁷ may add additional insights into the relations of alterations in fat, skeletal muscle, and bone mass with HF. Higher epicardial and visceral fat has been shown to have a stronger association with HFpEF risk compared with elevated subcutaneous fat.¹³⁸ Future developments in this field include to extend spatial fat tissue radiomics to HF incidence and outcomes.¹³⁹

Cardiac imaging

Obesity can complicate echocardiographic procedures and image acquisition, and therefore important considerations are needed when interpreting echocardiographic measures in these individuals. Indexing left atrial volume as well as LV volume and mass for body surface area may lead to underestimation of left atrial dilatation and LV hypertrophy in individuals with obesity, and consequently

affect the diagnostic and prognostic role of echocardiography in patients with or with suspected HF. Heighted-based indexing might be a valid option for more properly assessing left atrial size (or using lower body surface area-indexed thresholds) as well as LV mass in these patients.¹⁴⁰ Increased epicardial and pericardial fat is more common in patients with obesity and HFpEF.^{141,142} In patients with HFpEF, an epicardial adipose tissue thickness of 9 mm or more has been associated with poorer metabolic profile, pericardial restraint, and elevated cardiac filling pressures.^{141–143} Greater epicardial fat mass is associated with more LV dysfunction and fibrosis, as well as worse outcomes, in HFpEF but not HFrEF.^{144,145} The measurement of epicardial fat could be useful for patient characterization and prognostication, and since the adipocyte hyperplasia rather than adipocyte hypertrophy is the main mechanism of adipocyte remodelling in the epicardium,¹⁴⁶ it may be an emerging therapeutic target.¹⁴⁷

Use of echocardiographic contrast can improve image acquisition and may be particularly useful in individuals with obesity where image acquisition can be challenging. Cardiac magnetic resonance (CMR) is a viable alternative test to echocardiography to assess LV/right ventricular function as well as investigating the cause of HF by performing myocardial tissue characterization and rule out underlying significant coronary artery disease.^{148,149} Importantly, excessive BMI or WC may limit accessibility to MRI machines, so technical limitations need to be considered when prescribing CMR in severe obesity.

Exercise capacity

Exercise testing has a key risk stratification role in patients with HF. However, the assessment of exercise performance in obesity can be influenced by several factors. Obesity is commonly associated with other comorbid conditions (e.g. diabetes, sleep apnoea, musculoskeletal disease), which complicates the assessment of the independent role of obesity on cardiac performance during exercise.^{150,151}

Performing cardiopulmonary exercise testing in individuals with obesity is challenging. Peak oxygen consumption (VO_2) is conventionally indexed to body weight and reported as ml/kg/min. However, indexing exercise performance parameters to very large body weights can overemphasize the effects of scaling,^{152,153} leading to retrieve an exaggerated exercise limitation in individuals with obesity. Indeed, in obese individuals, body fat is substantial but at the same time consumes almost no oxygen. Therefore, indexing to lean body mass might provide a better measure of exercise capacity and might be a better prognosticator.¹⁵⁴ A submaximal parameter, such as minute ventilation-to-carbon dioxide output (VE/VCO_2) slope, may better risk stratify patients with obesity and HFrEF.⁴²

Prognostic role of weight reduction

Intentional weight loss in individuals with obesity with or without HF significantly reduces cardiovascular risk and improves outcomes, and can enhance mobility and quality of life

(QoL).^{155–159} However, in patients with HF, weight loss can also be non-intentional and a marker of disease progression. Cachexia is known to be associated with worse outcomes and reduced exercise capacity. Several strategies have been proposed to counteract cachexia such as exercise, nutrition, appetites stimulants, anti-inflammatory drugs (including antibodies against GDF-15),¹⁶⁰ and muscle regeneration.¹⁶¹ Still, in patients with obesity and HF, intentional body weight reduction, achieved through a combination of dietary modifications and exercise, plays a pivotal role in preserving muscle mass and improving exercise tolerance. On the contrary, if skeletal muscle mass and function is not preserved, that is skeletal muscle wasting, functional parameters as peak VO_2 and 6-min walking distance, as well as long-term prognosis, are further impaired.¹⁰⁶ Prevalence of skeletal muscle wasting varies among HF populations, involving around 20% of patients with chronic HF and ~30% of those with acute decompensated HF.¹⁰⁷ While skeletal muscle wasting is more pronounced in HFrEF due to reduced cardiac output, molecular alterations, and catabolic wasting processes which are typical of advanced HF, it remains relevant also in HFpEF, especially due to pro-inflammatory cytokine activation, renin–angiotensin–aldosterone system overactivity, obesity and insulin resistance, all of which accrue to the metabolic burden of this syndrome. These molecular alterations may deeply contribute to exercise intolerance in both HFrEF and HFpEF.¹⁰⁹ Therefore, the role of physical activity and exercise training in HF is crucial not only to promote a proper intentional body weight reduction, which leads to better prognosis, but also to contrast skeletal muscle wasting, cachexia and frailty.¹⁶²

Treatments for obesity

Rationale for treating obesity in heart failure

Obesity is a common and treatable comorbidity in patients with HF. Rather than a condition simply related to lifestyle, it must be considered a disease and treated as such.^{3,163,164} Treating obesity might ameliorate inflammation, insulin resistance, and hypertension, that is key mechanisms that link obesity with HF. Weight loss has been observed to be beneficial in different populations of patients with HFpEF and HFrEF,¹⁶⁵ prompting the Heart Failure Society of America to advise a 5–10% weight loss in patients with HF and BMI $\geq 35 \text{ kg/m}^2$, regardless of EF.¹⁶⁶

In both HFpEF and HFrEF, weight loss strategies, including lifestyle changes, pharmacological and surgical interventions, might reduce symptoms, improve exercise capacity, and reduce the risk of hospitalization for HF (Table 1),^{167–177} as well as they can represent a ‘bridge to advanced therapy’, for example for LV assist device and heart transplantation in HFrEF, when a high BMI is an exclusion criterion.^{166,178–182} Targeting obesity may be particularly important in HFpEF, given the specific pathophysiology and the high interplay between metabolic conditions and the clinical phenotype.

Exercise interventions

Improving exercise capacity is a cornerstone in the management of obesity, and is associated with improved survival in patients

Table 1 Selected trials investigating pharmacological or lifestyle interventions on weight loss in patients with HF

Trial	Sample size	Pharmacological/lifestyle intervention	Comparator arm	Effect on weight loss	Other key findings	Population
Pharmacotherapy						
Beck-da-Silva <i>et al.</i> ¹⁶⁷	21	Orlistat 120 mg 3x/d	Usual care	Weight loss -8.55 with orlistat vs. control, $p < 0.001$	Orlistat vs. usual care improved cardiometabolic risk factors, NYHA class, and 6MWT, but not QoL	HFpEF, BMI $> 30 \text{ kg/m}^2$
STEP-HFpEF ¹⁶⁸	529	Semaglutide (2.4 mg once weekly)	Placebo	13.3% vs. 2.6% reduction in body weight ($p < 0.001$)	6MWD increase, improved KCCQ-CSS, reduced CRP, reduced NT-proBNP	LVEF $\geq 45\%$, BMI $\geq 30 \text{ kg/m}^2$, no T2DM
STEP-HFpEF DM ¹⁶⁹	616	Semaglutide (2.4 mg once weekly)	Placebo	9.8% vs. 3.4% reduction in body weight ($p < 0.001$)	6MWD increase, improved KCCQ-CSS, reduced CRP, reduced NT-proBNP	LVEF $\geq 45\%$, BMI $\geq 30 \text{ kg/m}^2$, with T2DM
SUMMIT ¹⁷⁰	731	Tirzepatide (5, 10, or 15 mg)	Placebo	15.7% vs. 2.2% reduction in body weight ($p < 0.001$)	Improved both primary endpoints (urgent HF visit, HF hospitalization, oral diuretic intensification, and CV death; change in KCCQ-CSS)	HFpEF, obesity, age ≥ 40 years
Lifestyle modification						
SECRET ¹⁷¹	100	Caloric restriction (350–400 kcal/day deficit, 1.2 g protein per kg) and/or aerobic exercise 3x/week (walking/cycling 30–45 min)	Usual care	Diet main effect: -7 kg, $p < 0.001$ Exercise + diet: -11 kg, $p < 0.001$	Both diet and exercise improved peak VO_2 . Diet and exercise had additive effect	HFpEF, BMI $\geq 30 \text{ kg/m}^2$, age ≥ 60 years
Evangelista <i>et al.</i> ¹⁷²	14	HP hypocaloric diet or SP hypocaloric diet (walking/cycling 30–45 min)	Normocaloric diet	Greatest weight reduction with HP hypocaloric diet (-9.9 kg) vs. SP hypocaloric diet (-5.6 kg) vs. normocaloric diet (+1.5 kg), $p < 0.001$	HP hypocaloric diet had greatest percent body fat, total cholesterol, triglycerides, LDL cholesterol, and greater improvements in 6MWT, peak VO_2 , and QoL	HFpEF, T2DM, BMI $> 27 \text{ kg/m}^2$
Evangelista <i>et al.</i> ¹⁷³	99	Graduated, low-level exercise protocol ≥ 4 times weekly consisting of light aerobic exercise and resistive training	Usual care	Greatest weight reduction in exercise group (-6.37 kg vs. -0.33 kg, $p = 0.002$)	No significant differences in 6MWT or depression	BMI -27 kg/m ² , advanced HF
Gonzalez-Islas <i>et al.</i> ¹⁷⁴	88	Low-carbohydrate normocaloric diet	Normocaloric diet	No significant weight loss	No significant difference in handgrip strength	HF, any EF (35% had obesity)
Pro-HEART ¹⁷⁵	76	HP hypocaloric diet (30% protein, 40% carbohydrate, 30% fat)	SP hypocaloric diet (15% protein, 55% carbohydrate, 30% fat)	Equivalent weight loss (-3.6 vs. -2.8 kg) and reduction in waist circumference (-1.9 vs. -1.3 cm)	HP hypocaloric diet exhibited greater decreases in HbA1c, total cholesterol, and triglycerides	HF, any EF, DM, BMI $> 27 \text{ kg/m}^2$
Brubaker <i>et al.</i> ¹⁷⁶	88	Resistance and aerobic training plus 300 kcal/day deficit 3x/week + diet (500–750 kcal/d deficit)	Aerobic training plus 300 kcal/d deficit	No significant differences in body weight or body fat	Peak VO_2 increased to similar degree in both groups	HFpEF, BMI $\geq 28 \text{ kg/m}^2$, age ≥ 60 years
Pritchett <i>et al.</i> ¹⁷⁷	20	The lifestyle intervention modelled on the Look AHEAD trial's behavioural programme including portion-controlled diet modification, behavioural techniques, physical activity, and social support	Usual care	No significant between-group difference in weight change	No significant difference in other defined endpoints	HFpEF (EF $\leq 50\%$), BMI $\geq 25 \text{ kg/m}^2$

6MWD, 6-min walk distance; 6MWT, 6-min walk test; BMI, body mass index; CRP, C-reactive protein; CV, cardiovascular; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFREF, heart failure with reduced ejection fraction; HP, high-protein; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire clinical summary score; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; QoL, quality of life; SP, standard-protein; T2DM, type 2 diabetes mellitus; VO_2 , oxygen consumption.

at risk of cardiovascular disease.¹⁸³ Few randomized clinical trials (RCTs) have provided data on the effects of weight loss achieved by exercise training in obese patients with HF (Table 7). The effects of exercise interventions are likely depending on whether the programme is supervised (allowing more structured guidance, support, and possibly adherence) or unsupervised (less resources required), duration, frequency, mode of exercise (e.g. resistance training, aerobic training, high-intensity interval training), and the ability of the patient to safely tolerate and adhere to the programme. In the SECRET randomized trial, which used a factorial design to assess diet (350–400 kcal/day deficit, 1.2 g of protein per kg/day) and/or supervised exercise (three times 1 h per week, mainly walking) in 100 patients with obesity and HFrEF, exercise and diet had an additive effect on weight loss and peak VO_2 .¹⁷¹ In a post-hoc analysis of the HF-ACTION randomized trial (2331 patients with HFrEF), 3 months of three weekly supervised aerobic exercise sessions had only negligible effects on weight loss regardless of BMI but with a significant improvement in QoL.¹⁸⁴ In a smaller RCT on 99 overweight/obese patients with HFrEF, a 6-month home-based low-level aerobic exercise programme ≥ 4 times weekly resulted in greater weight loss (−6.37 vs. −0.33 kg) than the control group.¹⁷³

However, the benefits of exercise programmes in patients with obesity and HF extend well beyond weight loss, which should not be the sole target in treating obesity in HF. According to the 2021 ESC guidelines for HF, exercise is recommended in all patients with HF who are able to improve exercise capacity, QoL, and reduce HF hospitalizations.¹¹⁰ The REHAB-HF trial demonstrated that a transitional exercise rehabilitation programme improved physical function in 349 patients hospitalized for HF. In REHAB-HF, the mean BMI was 33 kg/m² and BMI did not interact with the intervention's effect, suggesting that this evidence is likely highly applicable to obese patients with HF.¹⁸⁵ In meta-analyses, even short-term programmes (3–6 months) of supervised exercise training could improve peak VO_2 , exercise duration, 6-min walking distance, and ultimately QoL in HFrEF.^{186–189} Thus, exercise training should be promoted in patients with obesity and HF to improve functional capacity and QoL, and may be a useful supplement to other strategies to promote weight loss.

Diet interventions

Caloric restriction is an effective strategy for weight loss. It stimulates autophagy and mitophagy, downregulates the mTOR pathway and activates AMP-activated protein kinase.¹⁹⁰ This, in turn, leads to improvements in several cardiovascular risk factors, such as hypertension and adiposity,¹⁹¹ and at least partially, to reversing the cardiometabolic syndrome.¹⁹² In a randomized study in elderly obese patients with multiple comorbidities, the CROSSROADS trial, caloric restriction improved quality of life and reduced total body fat and cardiometabolic risk factors, but did not significantly change body mass composition.¹⁹³ In patients with obesity and diabetes, but without history of HF, lifestyle modifications for weight loss have shown mixed results. While these interventions improve metabolic control and reduce the requirements for antidiabetic drugs, they do not always translate into a reduction of

cardiovascular events, highlighting the complexity of these conditions and the need for tailored approaches.¹⁹⁴ In the Look AHEAD trial, which tested an intensive lifestyle intervention promoting weight loss through decreased calorie intake and increased physical activity versus a support and education strategy for diabetes, there was no change in the incidence of cardiovascular events in overweight or obese patients with T2DM.¹⁹⁵ However, in a secondary analysis of the Look AHEAD trial, the intensive lifestyle modification was associated with a lower risk of cardiovascular events in patients who had a sustained weight loss.¹⁹⁶

Fewer studies have evaluated dietary modifications specifically in patients with obesity and established HF. Besides the reduction in the absolute calorie count, it is key to maintain an adequate muscle mass to avoid compromising metabolic health and physical function, and skeletal muscle wasting in HF.¹⁰⁶ In 76 overweight/obese patients with HF across the EF spectrum and diabetes enrolled in the Pro-HEART randomized trial, both high-protein and standard protein calorie-restricted diets resulted in weight loss, but the high-protein calorie-restricted arm showed greater improvements in cardiometabolic risk factors.¹⁷⁵ In the SECRET trial,¹⁷¹ the main effect of diet resulted in reduced weight and WC while improving body composition with increased lean body mass percentage. The diet + exercise arm showed the greatest reductions in weight and improvements in peak VO_2 . Trials evaluating diet and exercise interventions for weight loss in patients with HF are summarized in Table 7, and in aggregate may suggest that the combination of adequate protein intake, caloric restriction, and exercise training is more effective than any strategy alone in reducing obesity and its related health risks.

Success of dietary interventions is highly dependent on adherence, which is hard to achieve for caloric restriction. In a study evaluating a 15-week weight loss programme supported by counselling and meal replacements in 60 patients with HFrEF and obesity, only two-third completed the programme, but those who did lose weight experienced improved exercise capacity and QoL.¹⁹⁷ This highlights both the challenges and importance of patient counselling, education, support, and adherence strategies (e.g. promoting satiety by increased fibre and protein intake) to target weight loss. Remote disease management and/or telemonitoring also represent promising tools to achieve patient empowerment and facilitate adherence for lifestyle interventions. The ongoing IDEAL-HF trial is investigating the use of a diet management app together with an intelligent weight scale in an estimated 830 patients with obesity and HFrEF, with a hierarchical primary endpoint (NCT06455878).

Ketogenic diets and intermittent fasting have been popular alternatives among those seeking to lose weight in the general population. Cardiac metabolism in HF may be more efficient if energy is derived from ketones, which have further been suggested to suppress cardiac inflammation, leading to hypotheses that increasing circulating KBs (e.g. by ketogenic diets) may have beneficial effects in HF.¹⁹⁸ However, there is a lack of clinical trial data on ketogenic and intermittent-fasting diets in HF.¹⁹⁹ Both these diets warrant special safety considerations in patients with HF as they may carry risk for ketoacidosis in insulin-deficient patients or sodium–glucose cotransporter 2 inhibitor (SGLT2i) users, hypoglycaemia in insulin users, and electrolyte abnormalities. Ketogenic

diets entail restricted carbohydrate intake, which has been associated with higher mortality in observational studies, although with minimal risk observed at 50–55% carbohydrate intake.²⁰⁰ Patients with HF who adopt ketogenic diets should be closely monitored for electrolyte abnormalities, KBs, and elevated low-density lipoprotein cholesterol.²⁰¹ Moreover, considering that ketone oxidation is increased in the heart in HFrEF but is reduced in HFpEF, ketogenic diets may have different effects in these two populations, highlighting the importance of dedicated trials separately assessing the efficacy of these diets for a personalized prescription.

Pharmacological treatment of obesity in heart failure

Classical anti-obesity medications

Prior pharmacological treatments for obesity have seen limited use among patients with HF, partly due to concerns for cardiovascular safety. Fenfluramine was linked with the development of valve disease, sibutramine with elevated heart rate and blood pressure, cerebrovascular and myocardial infarctions, and phentermine with elevated heart rate and blood pressure, and are thus considered inappropriate to treat obesity in patients with HF.^{202,203} Bupropion sustained release–naltrexone produced modest weight loss in obese patients, but can increase heart rate and blood pressure, and has undetermined safety in HFrEF.²⁰⁴ Orlistat facilitated 8.6 kg weight loss, improved cardiometabolic risk factors, was safe, and improved exercise capacity in a small trial on 21 patients with HFrEF and obesity.¹⁶⁷ However, orlistat use predisposes patients to foecal urgency and steatorrhea, limiting compliance to this treatment.

Sodium–glucose cotransporter 2 inhibitors

Recent years have seen the introduction of new drug classes that have shown efficacy in terms of weight loss as well as of reduction in cardiovascular risk, representing a compelling opportunity to target weight loss in HF by pharmacological treatment.

Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident HF in patients with T2DM and high cardiovascular risk, and reduce the risk of cardiovascular mortality/HF hospitalizations in patients with HF across the EF spectrum.²⁰⁵ SGLT2i had consistent effect across the BMI spectrum in patients with HFrEF and HFpEF in post-hoc analyses of the DAPA-HF and DELIVER trials.^{206,207} SGLT2i also facilitate a modest but consistent weight loss.²⁰⁸ The results of network meta-analyses suggest reductions in body weight, as compared with placebo, for all SGLT2i of about 1.5–2.0 kg in patients with T2DM.^{209,210} Similar degrees of weight loss have been reported in patients with HFrEF and HFpEF.^{206,207} In patients with HFpEF in the DELIVER trial, patients with higher BMI experienced greater weight loss and improvement in QoL with dapagliflozin.²⁰⁷

Glucagon-like peptide-1 receptor agonists

In T2DM, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce risk of major adverse cardiovascular

events (MACE), that is a composite of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke (0.5/1 mg weekly semaglutide vs. placebo: 24% lower risk²¹¹; 1.8 mg daily liraglutide vs. placebo: 13% lower risk).²¹² GLP-1 RAs have a dose-dependent weight loss effect by promoting satiety, reducing appetite, slowing gastric emptying, and enhancing insulin secretion and energy expenditure. In patients with obesity, GLP-1 RAs have been demonstrated to produce significant weight loss when used at high doses (2.4 mg semaglutide weekly vs. placebo: 12.4% more weight loss²¹³; 3.0 mg liraglutide daily vs. placebo: 5.6 kg more weight loss).²¹⁴ In patients with obesity but without T2DM in the SELECT trial (BMI ≥ 27 kg/m²), 2.4 mg weekly semaglutide was shown to lower the risk of MACE (a composite of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke) by 20%.¹⁵⁷ The effect on these outcomes was shown before meaningful weight loss occurred, suggesting that GLP-1 RAs convey some cardiovascular benefits through weight loss-independent mechanisms, which may include improving metabolic parameters such as glycated haemoglobin, blood pressure, and lipid profiles.^{215–217} They may also improve endothelial function and may ameliorate myocardial relaxation, reduce fibrosis, and inhibit oxidative stress and inflammatory pathways.^{216,218}

In patients with HFpEF and obesity, recent trial data suggest that semaglutide, beyond promoting weight loss, can improve QoL and exercise capacity. In the STEP-HFpEF trial, patients with obesity (BMI ≥ 30 kg/m²) and HFpEF (EF $\geq 45\%$) without diabetes assigned to semaglutide experienced greater weight loss (13.3% vs. 2.6%), and improvement in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS, +16.6 vs. +8.7 points) and 6-min walk distance (+21.5 vs. +1.2 m) as compared with placebo. The benefits were consistent irrespective of EF and baseline BMI.¹⁶⁸ Semaglutide also had favourable effects on the hierarchical composite endpoint including all-cause mortality, HF events, improvements in functional capacity and exercise tolerance.¹⁶⁸ In the STEP-HFpEF DM trial, which enrolled patients with obesity, HFpEF, and diabetes, treatment with semaglutide achieved slightly less weight reduction (9.8% with semaglutide vs. 3.4% with placebo) but similar effect on KCCQ-CSS, 6-min walk test, and NT-proBNP as in STEP-HFpEF.¹⁶⁹ Weight loss would typically be expected to be linked with an increase in NT-proBNP given the inverse relationship between NT-proBNP levels and BMI. Therefore, the observation that semaglutide users in the STEP-HFpEF programme experienced greater reductions in NT-proBNP might suggest that some of the benefits were mediated by factors other than weight loss. This view was recently supported by an echocardiography sub-study of the STEP-HFpEF programme, where semaglutide appeared to reduce adverse left atrial and right ventricular remodelling, without affecting LV dimensions or mass.²¹⁹ A recent pooled analysis included all patients from the STEP-HFpEF ($n = 529$) and STEP-HFpEF DM ($n = 616$) trials, as well as the HFpEF subgroups from the SELECT ($n = 2273$) and FLOW ($n = 325$) trials.²²⁰ In 3743 patients with HFpEF, semaglutide reduced the risk of cardiovascular death/worsening HF events by 31%, worsening HF events by 41%, with non-significant effect on cardiovascular death (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.57–1.16). These data must, however, be considered mainly as hypothesis generating

because of the low number of primary outcome events ($n = 241$, event-rate per 100 person-years 2.1 with semaglutide and 3.0 with placebo), and the lack of systematic characterization of HF at baseline in SELECT and FLOW.

The dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA tirzepatide was evaluated against placebo in patients with BMI >27 kg/m² in the SURMOUNT-1 trial, reporting even greater efficacy on weight loss (-15.0% to -20.9% with 5 to 15 mg weekly tirzepatide vs. -3.1% with placebo).²²¹ The SUMMIT trial was a pivotal study evaluating the efficacy of tirzepatide in patients with HFpEF and obesity. This international, double-blind, randomized, placebo-controlled trial enrolled 731 patients who were assigned to receive either tirzepatide or placebo over a median follow-up of 104 weeks. Tirzepatide significantly reduced the incidence of the primary composite endpoint of death from cardiovascular causes or worsening HF events, with events occurring in 9.9% of the tirzepatide group as compared with 15.3% in the placebo group (HR 0.62, 95% CI 0.41–0.95).¹⁷⁰ This benefit was primarily driven by a decrease in worsening HF events.

Secondary analysis of the SUMMIT trial highlighted mechanistic insights, indicating an improvement in volume overload (lowered estimated blood volume by 0.58 L) and reduction in systolic blood pressure by 5 mmHg.²²² A reduction in troponin T and NT-proBNP levels, together with an improvement in estimated glomerular filtration rate by 2.90 ml/min/1.73 m² were also observed.²²² CMR findings showed reductions in LV mass and paracardiac adipose tissue with tirzepatide versus placebo.²²³

Overall, these data indicate a role for the use of semaglutide or tirzepatide in obesity-related HFpEF for effective weight loss as well as for improvement in symptoms and hard clinical outcomes. Importantly, a reduction in muscle mass (or in fat-free mass) has been observed in patients receiving GLP-1 RAs for weight loss, with higher levels than what observed in patients losing weight with alternative strategies, as well as in the SUMMIT trial in patients with HFpEF and obesity.²²⁴ Whether this effect is really detrimental²²⁵ or what is the impact in the context of HF warrants further investigations.

For patients with HFrEF, the evidence for treating obesity with GLP-1 RAs is less certain and their safety is debated. In the FIGHT trial, patients recently hospitalized for HFrEF with low EF (mean EF 27%) randomized to liraglutide experienced a numeric but non-significant increase in HF hospitalizations.²²⁶ Similarly, in the LIVE study, patients with chronic HFrEF assigned to liraglutide had increased risk of adverse cardiac events, although there was only one death and one HF hospitalization, and the overall number of adverse cardiac events was low (12 [10%] with liraglutide vs. 3 [3%] with placebo, $p = 0.04$).²²⁷ However, neither FIGHT nor LIVE were trials focusing on an obese HFrEF population, and the GLP-1 RAs were not given in an obesity dose. In contrast, in a recently published post-hoc analysis of SELECT including 1347 patients with HFrEF (mean BMI 33.4 kg/m²), semaglutide reduced the risk of MACE by 35% and of the composite of cardiovascular death or hospitalization or urgent HF hospital visit by 21%, although the effect on HF hospitalizations alone was non-significant (HR 1.08; $p = 0.11$).²²⁸ Importantly, patients with HF and New York Heart Association (NYHA) class IV were excluded, and ~60% had

NYHA class II and, consistently, the rate of adverse events during follow-up was low (MACE $n = 205$, rate per 100 person-years 3.9 with semaglutide and 6.0 with placebo), indicating a less severe HF population than typically enrolled in modern HF trials. It should be noted that GLP-1 RAs, including semaglutide, are associated with a slight increase in heart rate (3–5 bpm).^{157,229} Overall, incretin-based therapies should be tested in obese HFrEF populations in prospective, appropriately designed RCTs.²³⁰

Mechanistic RCTs of incretin-based therapies in obese HFrEF populations are warranted investigating effects on body composition (including adipose tissue in different organs and skeletal muscle), rhythm (atrial and ventricular dysrhythmias and heart rate) and effects on cardiac and kidney function. Robustly powered outcome RCTs are also necessary in obese HFrEF populations to determine the efficacy and safety of incretin-based therapies. Trials with various agents could target different body weights and use different pharmacological weight-loss strategies. These trials might avoid patients with very severe HFrEF (such as those enrolled in FIGHT).²²⁶

Treatment of obesity by bariatric surgery in heart failure

Bariatric surgery is well-established as an efficient intervention to achieve weight loss in obese patients without pre-existing HF. In the GETAWAY trial, which randomized 100 obese hypertensive patients to bariatric surgery plus medical therapy versus medical therapy alone, bariatric surgery was an effective strategy to achieve better blood pressure control, cardiometabolic profile and reduce polypharmacy associated with obesity and cardiometabolic disease, both in the short and long term.^{231,232} In patients with diabetes and obesity, without pre-existing HF, observational studies have suggested bariatric surgery to reduce the risk of incident HF.^{233,234} Furthermore, sustained weight loss achieved with gastric bypass surgery is associated with a reduced risk of cardiovascular events, including the development of HF.²³⁵

To date, RCTs on bariatric surgery in patients with established HF are lacking, and evidence is therefore limited to observational studies. Prior bariatric surgery was associated with lower in-hospital mortality and shorter hospitalization duration in patients with obesity and HFpEF or HFrEF admitted due to decompensated HF,^{236,237} especially if they had successfully lost weight. In obese patients with HFpEF, bariatric surgery was also associated with improved diastolic function, functional improvement, and lower readmission rates.^{238–241} In a propensity-matched Canadian cohort study, bariatric surgery was associated with 56% lower risk of MACE (a composite of myocardial infarction, ischaemic stroke and all-cause mortality) in the subgroup with pre-existing HF.²³³ In a systematic meta-analysis of observational studies on patients with obesity, bariatric surgery was associated with a 45% reduction in all-cause mortality, 41% reduction in cardiovascular mortality and 50% reduction in the incidence of HF.²⁴²

However, bariatric surgery carries potential surgical-related risks of complications, may promote nutritional deficiency requiring supplementation, and is available only in specific centres.²⁴³ In observational studies on bariatric surgery, HF was associated

with an eight-fold higher risk of intraoperative cardiovascular complications (absolute risk increase of 1.2%),²⁴⁴ and HFrEF with a three-fold higher risk of in-hospital mortality.²⁴⁵ Therefore, the indication for bariatric surgery should be tailored to a case-by-case scenario. Further prospective RCTs tailored on the specific HF phenotypes and HF severity are needed to inform on acceptable risk thresholds for bariatric surgery in patients with HF. The ongoing BRAVE trial will assess bariatric surgery in an anticipated 2000 patients with severe obesity (BMI >35 kg/m²) and high-risk cardiovascular disease (including HFrEF and HFpEF), with MACE as primary outcome (NCT05531474).

Other medical treatments for heart failure in patients with obesity

Obese patients represent overall up to 40% of patients with HFrEF, however they are underrepresented in RCTs.²⁴⁶ In HFrEF, consistent effect across the BMI spectrum has been reported for SGLT2i,²⁰⁶ and mineralocorticoid receptor antagonists (MRAs) potentially have greater benefit in those with abdominal obesity.²⁴⁷ Although angiotensin receptor–neprilysin inhibitor efficacy was not examined across BMI subgroups in the PARADIGM-HF, the mean BMI in this trial was 28 kg/m², suggesting generalizability of results to the overweight/obese population. Guideline-directed medical treatments are consistently recommended across the BMI spectrum.^{110,248,249} However, obesity may affect the tolerability profile and pharmacodynamics of different drugs.²⁵⁰ Indeed, obesity is associated with a higher activation of the renin–angiotensin–aldosterone system, more sympathetic stimulation and synthesis of adipokines, and a different response to MRAs.^{251–254} Furthermore, in obese patients, the rate of absorption of several medications may be slowed due to delayed gastric emptying, the increased volume of distribution of lipophilic drugs and the changes in plasma protein level together with altered liver metabolism and excretion mechanism may impact the pharmacokinetics and pharmacodynamics of several HF drugs.²⁵⁵ Data from large HF registries, including SwedeHF,⁴⁴ CHAMP-HF,³¹ CHECK-HF,²⁵⁶ and BIOSTAT-CHF,²⁵⁷ suggest that obese patients are more frequently achieving target doses of guideline-directed medical therapies, potentially due to better tolerability, and this may be associated with improvement in longer-term outcomes.

In HFpEF, the only pharmacological class with a current class I recommendation to reduce HF hospitalizations or cardiovascular mortality, SGLT2i, has also demonstrated consistent effect regardless of BMI.²⁰⁷ The recently delivered FINEARTS-HF trial showed the efficacy of the non-steroidal MRA finerenone in reducing worsening HF events or cardiovascular mortality by 16% in 6001 patients with HFpEF or HFmrEF.²⁵⁸ Mineralocorticoid receptor blockade might be particularly appealing in obesity-related HFpEF, where adipocyte aldosterone production can contribute to mineralocorticoid receptor overactivation.^{61,62}

Clinical trial design

Clinical trial design for patients with obesity is becoming important considering the number of different interventions and novel agents

that are currently available in the pipeline and in need of being tested. These include existing but understudied interventions (such as specific lifestyle intervention programmes and bariatric surgery), novel pharmacological weight-loss treatments (such as novel GLP-1 RAs, GIP agonists, amylin agonists, glucagon agonists, peptide YY agonists, and combination therapies), and therapies targeting muscle wasting/cachexia which might occur in conjunction with weight loss (such as GDF-15 antagonists). Certain considerations that are very specific to obesity treatments need to be made in the design of such trials.

Heart failure trials have become increasingly reliant on inclusion criteria based on natriuretic peptides to ensure that enrolled patients have HF. The need for objective diagnostic criteria for HF diagnosis is perhaps even greater in HF trials on obesity, since symptoms between these two entities overlap. Determining appropriate cut-offs for natriuretic peptides in the obese population is, however, complicated by the inverse relationship between BMI and natriuretic peptides. Cut-offs stratified by BMI might be a feasible approach to address this issue. Alternatively, other objective criteria, such as right heart catheterization, might also be appropriate.

The effect of most evidence-based HF drugs to date is greater or only evident in HFrEF versus HFpEF (SGLT2i being the notable exception). Given the differential pathophysiological role of obesity and downstream metabolic factors in HFrEF versus HFpEF, it is plausible that many weight-loss treatments might also have effects that vary across the EF spectrum. Trials should therefore be encouraged to achieve sufficient power to investigate these phenotypes separately.

A perpetual question in trials on obese HF is whether the benefits that are being seen with obesity-modifying therapies are related to the drug directly affecting the cardiovascular system, or simply to weight loss. Mechanistic studies aiming to distinguish between these two factors may be helpful. Such studies might use as endpoints biomarkers and imaging (e.g. echocardiography, MRI, CT) to assess diastolic/systolic function, inflammation, fibrosis, and fat distribution (including epicardial adipose tissue). However, as outlined in previous sections, most if not all these endpoints can also change as an indirect effect of weight loss. Active control arms achieving similar degrees of weight loss as the studied intervention are therefore encouraged to identify potential direct cardiovascular effects.

Trials seeking to generate evidence for therapeutic indications might consider a range of outcomes that are both clinically relevant and plausible targets for weight-loss therapies, since obesity affects health status and outcomes both directly and through intermediary cardiometabolic steps. Death and worsening HF events remain the most accepted relevant clinical endpoints for the HF population. However, since obesity-modifying drugs tend to effect different organ systems and diseases, sufficiently powered trials might consider evaluating multiple endpoints in different organ systems, for instance reduction of cardiovascular outcomes and chronic kidney disease outcomes within the same clinical trial rather than focusing on one type of outcome per trial. In previous HF trials, the effect of HF drugs on kidney endpoints were highly dependent on the definition of events, which thus needs to consider characteristics of both the investigational drug and the target population.²⁵⁹ Although

weight loss can be a valid therapeutic target for obese patients with HF, a demonstration of efficacy and safety on hard cardiovascular endpoints should precede widespread use in this population.

Patients with HF and obesity have substantial reductions in QoL and functional capacity,²⁶⁰ so along with improvement in clinical outcomes, improvement in functional capacity and QoL may be endpoints of dedicated studies. Robust measures of exercise capacity (such as the 6-min walk test, peak VO_2 , or VE/VCO_2 slope) and QoL (such as the KCCQ) should be preferred over more crude measures with less clear associations with hard clinical outcomes, such as changes in NYHA class.^{261–263} However, the profound weight loss exerted by GLP-1 RAs and GIP/GLP-1 RAs could reasonably risk unmasking treatment allocation, potentially warranting some caution when relying solely on soft endpoints.²³⁰ Moreover, improvements in exercise capacity and QoL may be a result of the weight loss *per se* rather than modification of underlying HF.

Another consideration is the control arm treatment with placebo or active drug, considering the positive studies including for clinical outcomes some of the drugs in this category.²²⁰ Comparative effectiveness of various drugs that impact obesity needs to be assessed. Because there is a difference in visceral adiposity distribution across different regions of the world – for example in South Asians, there is a higher visceral adiposity despite a lower BMI –²⁶⁴ a good representation and a broader group of BMI patients should be studied with these drugs to assess their generalizability. These trials are probably best designed by a multidisciplinary team that includes cardiologists, internists, endocrinologists, and other specialties with expertise in both clinical trial design and various clinical specialties. Consideration should be given to basket trials, umbrella trials, and platform trials to either assess multiple outcomes with a given drug or multiple drugs for a given outcome.

Conclusions

Obesity contributes to HF risk and is common in patients with established HF, where it adversely affects symptoms and QoL. The presence of obesity warrants a tailored approach throughout the HF disease journey, from prevention in pre-HF, diagnostic work-up of suspected HF, and treatment in established HF. Lifestyle modifications should balance the need for weight loss with the maintaining of lean muscle mass, and may be most effective when dietary and exercise interventions are combined. The advent of potent weight-loss therapies with simultaneous cardiovascular benefits, including GLP-1 RAs and GIP/GLP-1 RAs, have provided clinicians with new tools to pharmacologically treat obesity-related HFpEF. These therapies are potential alternatives also for selected patients with HFrEF and obesity, although more RCT data are needed.

Conflict of interest: G.S. reports grants and personal fees from Vifor, Boehringer Ingelheim, AstraZeneca, Novartis, Cytokinetics, Pharmacosmos, personal fees from Servier, Medtronic, TEVA, Laboratori Guidotti, INTAS, grants from Boston Scientific, Merck, Bayer, outside the submitted work. F.L. reports personal fees from AstraZeneca. A.B.G. reports personal fees or advisory boards from Abbott, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, Novo Nordisk, Roche Diagnostics, and Vifor

Pharma. M.B.'s institution has received speaker and consultant fees from Amarin, Amgen, Heel, Novartis, and Fresenius Kabi. F.B. reports participation in trial committees for Medtronic, Biotronik; speaker's bureau (contract with employer, no personal fees) for AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Orion, Abbott, Biosense Webster, Boston Scientific. C.B.D. is the CEO (part-time) of the Society for Cardiovascular Magnetic Resonance and received speaker fees from Circle Cardiovascular Imaging, Siemens Healthineers, GE Healthcare, Philips and Bayer. J.B. is consultant to Abbott, American Regent, Amgen, Applied Therapeutics, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Levator, Lexicon, Lilly, LivaNova, Janssen, Medtronic, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Roche, Salamandra, Salubris, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vascular Dynamics, Vifor, and Zoll. A.C. reports honoraria from Boehringer Ingelheim. O.C. reports Servier support for meetings. E.D.E. reports honoraria from Boehringer Ingelheim, AstraZeneca, Bayer. G.F. has been a committee member in trials for the European Commission; has received payment or honoraria from Bayer and Boehringer Ingelheim; has participated in a data safety monitoring board or advisory board from Bayer; has a leadership or fiduciary role from European Academy, Heart Failure Association, and JACC Heart Failure; and has received lecture fees, advisory or committee membership in trials from Amgen, Bayer, Boehringer Ingelheim, Cardior, Impulse Dynamics, Medtronic, Novartis, Servier, and Vifor. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer, Cardior, Lilly, Novartis, NP Medical, Novo Nordisk, Roche Diagnostics. J.S.H. reports institution fee from Pliant Thx, Sanofi, Servier and Novo Nordisk; speaker, advisory board or consultancy fees from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Vifor Pharma. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; received research support from Novo Nordisk and Roche Diagnostics; served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Alleviant Medical, Allysta Pharma, Alnylam Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Hanmi, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. L.H.L. reports grants, consulting, honoraria from Alleviant, Amgen, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Edwards, Novartis, Novo Nordisk, Owkin, Pharmacosmos, Vifor Pharma, outside the submitted work. C.M. reports honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novo Nordisk, Amgen, Servier, Bayer, Novartis, Edwards. B.M. reports speaker or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Novartis, Servier, and Viartaris. M.C.P. reports research funding from Boehringer Ingelheim, Roche, SQ Innovations, AstraZeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, Pharmacosmos; and has consultancy or trial committees for Abbott, Akero, Applied Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Corderia, Novartis, AstraZeneca, Novo Nordisk, Abbvie, Bayer, Horizon Therapeutics, Foundry, Takeda, Cardiorientis, Pharmacosmos, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, 3R Lifesciences, Reprieve, FIRE 1, Corvia, Regeneron. M.P. reports consultancy, speaker fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, payment for

writing or reviewing manuscripts from Menarini, Servier. M.B.Y. reports institutional fee from Novartis, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Albert Health. P.S. reports consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis, and Menarini; honorarium for lecture from AstraZeneca. C.G.T. reports honoraria or consultation fees from VivaLyfe, Univers Formazione, Solaris, Summeet, AstraZeneca, Myocardial Solutions, Medtronic; funding from Amgen and MSD; and is listed as an inventor of two patents related to HF, outside the submitted work. M.M. reports personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, WindTree Therapeutics, as member of trials' committees or advisory boards or for speeches at sponsored meetings in the last 3 years. All other authors have nothing to disclose.

References

- World Health Organization. Global Health Observatory (GHO) Data Repository. <https://apps.who.int/gho/data/node.main.A900A?lang=en>. Accessed 01 May 2025
- Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. *Lancet Diabetes Endocrinol* 2025;13:221–262. [https://doi.org/10.1016/S2213-8587\(24\)00316-4](https://doi.org/10.1016/S2213-8587(24)00316-4)
- Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al.; Obesity Management Task Force of the European Association for the Study of Obesity. European guidelines for obesity management in adults. *Obes Facts* 2015;8:402–424. <https://doi.org/10.1159/000442721>
- Prasad DS, Kabir Z, Suganthi JP, Dash AK, Das BC. Appropriate anthropometric indices to identify cardiometabolic risk in South Asians. *WHO South East Asia J Public Health* 2013;2:142–148. <https://doi.org/10.4103/2224-3151.206760>
- Rao G, Powell-Wiley TM, Anchara I, Hairston K, Kirley K, Lear SA, et al.; American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: A scientific statement from the American Heart Association. *Circulation* 2015;132:457–472. <https://doi.org/10.1161/CIR.0000000000000223>
- Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: A population-based cohort study of 3.6 million adults in the UK. *Lancet Diabetes Endocrinol* 2018;6:944–953. [https://doi.org/10.1016/S2213-8587\(18\)30288-2](https://doi.org/10.1016/S2213-8587(18)30288-2)
- GBD 2013 Risk Factors Collaborators Forouzanfar MH, Alexander L, Anderson H, Ross Bachman Victoria F, Biryukov Stan, Brauer Michael et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;386:2287–2323. [https://doi.org/10.1016/S0140-6736\(15\)00128-2](https://doi.org/10.1016/S0140-6736(15)00128-2)
- Tham KW, Abdul Ghani R, Cua SC, Deerochanawong C, Fojas M, Hocking S, et al. Obesity in South and Southeast Asia – a new consensus on care and management. *Obes Rev* 2023;24:e13520. <https://doi.org/10.1111/obr.13520>
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363:157–163. [https://doi.org/10.1016/S0140-6736\(03\)15268-3](https://doi.org/10.1016/S0140-6736(03)15268-3)
- Gray N, Picone G, Sloan F, Yashkin A. Relation between BMI and diabetes mellitus and its complications among US older adults. *South Med J* 2015;108:29–36. <https://doi.org/10.14423/SMJ.0000000000000214>
- Leggio M, Lombardi M, Caldarone E, Severi P, D'Emidio S, Armeni M, et al. The relationship between obesity and hypertension: An updated comprehensive overview on vicious twins. *Hypertens Res* 2017;40:947–963. <https://doi.org/10.1038/hr.2017.75>
- Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: Implications for total and cardiovascular mortality. *Ann Intern Med* 2015;163:827–835. <https://doi.org/10.7326/M14-2525>
- Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. *Circulation* 2015;132:1639–1647. <https://doi.org/10.1161/CIRCULATIONAHA.114.015000>
- Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. *Am J Clin Nutr* 2004;79:379–384. <https://doi.org/10.1093/ajcn/79.3.379>
- Darbandi M, Pasdar Y, Moradi S, Mohamed HJJ, Hamzeh B, Salimi Y. Discriminatory capacity of anthropometric indices for cardiovascular disease in adults: A systematic review and meta-analysis. *Prev Chronic Dis* 2020;17:E131. <https://doi.org/10.5888/pcd17.200112>
- Abdi Dezfouli R, Mohammadian Khonsari N, Hosseinpour A, Asadi S, Ejtahed HS, Qorbani M. Waist to height ratio as a simple tool for predicting mortality: A systematic review and meta-analysis. *Int J Obes (Lond)* 2023;47:1286–1301. <https://doi.org/10.1038/s41366-023-01388-0>
- Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. *Obes Facts* 2022;15:321–335. <https://doi.org/10.1159/000521241>
- Billingsley HE, Del Buono MG, Canada JM, Kim Y, Damonte JL, Trankle CR, et al. Sarcopenic obesity is associated with reduced cardiorespiratory fitness compared with nonsarcopenic obesity in patients with heart failure with reduced ejection fraction. *Circ Heart Fail* 2022;15:e009518. <https://doi.org/10.1161/CIRCHEARTFAILURE.122.009518>
- Carbone S, Billingsley HE, Rodriguez-Miguel P, Kirkman DL, Garten R, Franco RL, et al. Lean mass abnormalities in heart failure: The role of sarcopenia, sarcopenic obesity, and cachexia. *Curr Probl Cardiol* 2020;45:100417. <https://doi.org/10.1016/j.cpcardiol.2019.03.006>
- Eurostat. Overweight and obesity - BMI statistics. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Overweight_and_obesity_-_BMI_statistics. Accessed 02/04/25
- World Health Organization. Obesity in the WHO European region fact-sheet. <https://www.who.int/europe/publications/m/item/obesity-in-the-who-european-region-factsheet>. Accessed 02/04/25
- Centers for Disease Control and Prevention. Adult obesity prevalence maps. <https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html>. Accessed 02/04/25.
- Canadian Health Measures Survey. <https://www.statcan.gc.ca/o1/en/plus/5742-overview-weight-and-height-measurements-world-obesity-day>. Accessed 02/04/25.
- Lui DTW, Ako J, Dalal J, Fong A, Fujino M, Horton A, et al. Obesity in the Asia-Pacific region: Current perspectives. *J Asian Pacific Soc Cardiol* 2024;3:e21. <https://doi.org/10.15420/japsc.2023.68>
- Kenchiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. *N Engl J Med* 2002;347:305–313. <https://doi.org/10.1056/NEJMoa020245>
- Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. *J Am Coll Cardiol* 2017;69:1129–1142. <https://doi.org/10.1016/j.jacc.2016.11.081>
- Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Naylor M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. *JACC Heart Fail* 2018;6:701–709. <https://doi.org/10.1016/j.jchf.2018.05.018>
- Lam CSP, Chandramouli C. Fat, female, fatigued: Features of the obese HFpEF phenotype. *JACC Heart Fail* 2018;6:710–713. <https://doi.org/10.1016/j.jchf.2018.06.006>
- Walli-Attaei M, Joseph P, Johansson I, Sliwa K, Lonn E, Maggioni AP, et al.; G-CHF Investigators. Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: An analysis from the Global Congestive Heart Failure (G-CHF) registry. *Lancet Glob Health* 2024;12:e396–e405. [https://doi.org/10.1016/S2214-109X\(23\)00557-0](https://doi.org/10.1016/S2214-109X(23)00557-0)
- Powell-Wiley TM, Ngwa J, Kebede S, Lu D, Schulte PJ, Bhatt DL, et al. Impact of body mass index on heart failure by race/ethnicity from the Get With The Guidelines-Heart Failure (GWTG-HF) registry. *JACC Heart Fail* 2018;6:233–242. <https://doi.org/10.1016/j.jchf.2017.11.011>
- Greene SJ, Butler J, Albert NM, AD DV, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. *J Am Coll Cardiol* 2018;72:351–366. <https://doi.org/10.1016/j.jacc.2018.04.070>
- Stolfo D, Lund LH, Benson L, Hage C, Sinagra G, Dahlström U, et al. Persistent high burden of heart failure across the ejection fraction spectrum in a nationwide setting. *J Am Heart Assoc* 2022;11:e026708. <https://doi.org/10.1161/JAHA.122.026708>
- Malgie J, Wilde MI, Clephas PRD, Emans ME, Koudstaal S, Schaap J, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. *Eur J Heart Fail* 2024;26:1549–1560. <https://doi.org/10.1002/ehf.3267>
- Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. *JACC Heart Fail* 2022;10:184–197. <https://doi.org/10.1016/j.jchf.2021.11.006>
- Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, et al.; EMPEROR-Preserved Trial Committees and Investigators. Baseline characteristics of patients with heart failure with preserved ejection fraction in the

- EMPEROR-Preserved trial. *Eur J Heart Fail* 2020;**22**:2383–2392. <https://doi.org/10.1002/ehf.2064>
36. Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, et al.; Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: A meta-analysis of individual patient data. *Int J Obes (Lond)* 2014;**38**:1110–1114. <https://doi.org/10.1038/ijo.2013.203>
 37. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillich JH. The relationship between obesity and mortality in patients with heart failure. *J Am Coll Cardiol* 2001;**38**:789–795. [https://doi.org/10.1016/s0735-1097\(01\)01448-6](https://doi.org/10.1016/s0735-1097(01)01448-6)
 38. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. *J Am Coll Cardiol* 2017;**70**:2739–2749. <https://doi.org/10.1016/j.jacc.2017.09.1111>
 39. Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Waist-to-hip ratio and mortality in heart failure. *Eur J Heart Fail* 2018;**20**:1269–1277. <https://doi.org/10.1002/ehf.1244>
 40. Chandramouli C, Tay WT, Bamadhaj NS, Tromp J, Teng THK, Yap JLL, et al.; ASIAN-HF Investigators. Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. *PLoS Med* 2019;**16**:e1002916. <https://doi.org/10.1371/journal.pmed.1002916>
 41. Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, Køber L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: Revisiting the obesity paradox. *Eur Heart J* 2023;**44**:1136–1153. <https://doi.org/10.1093/eurheartj/ehad083>
 42. Piepoli MF, Corrà U, Veglia F, Bonomi A, Salvioni E, Cattadori G, et al.; MECKI Score Research Group. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: Data from the MECKI Score Research Group. *Eur J Heart Fail* 2016;**18**:545–553. <https://doi.org/10.1002/ehf.534>
 43. Grady KL, White-Williams C, Naftel D, Costanzo MR, Pitts D, Rayburn B, et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of preoperative weight-height indices. *Cardiac Transplant Research Database (CTRD) Group. J Heart Lung Transplant* 1999;**18**:750–763. [https://doi.org/10.1016/s1053-2498\(99\)00035-2](https://doi.org/10.1016/s1053-2498(99)00035-2)
 44. Cappelletto C, Stolfo D, Orsini N, Benson L, Rodolico D, Rosano GMC, et al. Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: Data from the Swedish Heart Failure Registry. *Eur J Heart Fail* 2023;**25**:698–710. <https://doi.org/10.1002/ehf.2795>
 45. Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, et al. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC. *Eur J Heart Fail* 2024;**26**:1278–1297. <https://doi.org/10.1002/ehf.3295>
 46. Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. *Int J Cardiol* 2018;**271**:132–139. <https://doi.org/10.1016/j.ijcard.2018.04.001>
 47. Tromp J, Claggett BL, Liu J, Jackson AM, Jhund PS, Køber L, et al.; PARAGON-HF Investigators. Global differences in heart failure with preserved ejection fraction: The PARAGON-HF trial. *Circ Heart Fail* 2021;**14**:e007901. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007901>
 48. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. *Eur Heart J* 2012;**33**:1750–1757. <https://doi.org/10.1093/eurheartj/ehr254>
 49. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006;**355**:251–259. <https://doi.org/10.1056/NEJMoa052256>
 50. Duflo J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. *Am Heart J* 1995;**130**:306–313. [https://doi.org/10.1016/0002-8703\(95\)90445-x](https://doi.org/10.1016/0002-8703(95)90445-x)
 51. Wohlfahrt P, Redfield MM, Lopez-Jimenez F, Melenovsky V, Kane GC, Rodeheffer RJ, et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. *JACC Heart Fail* 2014;**2**:489–499. <https://doi.org/10.1016/j.jchf.2014.03.014>
 52. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. *Arch Intern Med* 1981;**141**:81–85. <https://doi.org/10.1001/archinte.141.1.81>
 53. Shah AS, Khoury PR, Dolan LM, Ippisch HM, Urbina EM, Daniels SR, et al. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. *Diabetologia* 2011;**54**:722–730. <https://doi.org/10.1007/s00125-010-1974-7>
 54. Russo C, Jin Z, Homma S, Rundek T, Elkind MSV, Sacco RL, et al. Effect of obesity and overweight on left ventricular diastolic function: A community-based study in an elderly cohort. *J Am Coll Cardiol* 2011;**57**:1368–1374. <https://doi.org/10.1016/j.jacc.2010.10.042>
 55. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. *Circulation* 2017;**136**:6–19. <https://doi.org/10.1161/CIRCULATIONAHA.116.026807>
 56. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. *JACC Heart Fail* 2018;**6**:1008–1010. <https://doi.org/10.1016/j.jchf.2018.08.007>
 57. Sorimachi H, Obokata M, Takahashi N, Reddy YNV, Jain CC, Verbrugge FH, et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. *Eur Heart J* 2021;**42**:1595–1605. <https://doi.org/10.1093/eurheartj/ehaa823>
 58. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Ararat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. *Circulation* 2003;**108**:2460–2466. <https://doi.org/10.1161/01.CIR.0000099542.57313.C5>
 59. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokinases. *Eur Heart J* 2015;**36**:795–805a. <https://doi.org/10.1093/eurheartj/ehv099>
 60. Savarese G, Lindberg F, Filippatos G, Butler J, Anker SD. Mineralocorticoid receptor overactivation: Targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists. *Diabetologia* 2024;**67**:246–262. <https://doi.org/10.1007/s00125-023-06031-1>
 61. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. *N Engl J Med* 1981;**304**:930–933. <https://doi.org/10.1056/NEJM198104163041602>
 62. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: Implications in diabetes mellitus-associated obesity and vascular dysfunction. *Hypertension* 2012;**59**:1069–1078. <https://doi.org/10.1161/HYPERTENSIONAHA.111.190223>
 63. Balmann BN, Weinstein K, Bernhardt V, Marines-Price R, Tomlinson AR, Babb TG. Multidimensional aspects of dyspnea in obese patients referred for cardiopulmonary exercise testing. *Respir Physiol Neurobiol* 2020;**274**:103365. <https://doi.org/10.1016/j.resp.2019.103365>
 64. Bernhardt V, Babb TG. Exertional dyspnoea in obesity. *Eur Respir Rev* 2016;**25**:487–495. <https://doi.org/10.1183/16000617.0081-2016>
 65. Hagenburg J, Bertin E, Salmon JH, Thierry A, Perotin JM, Dormoy V, et al. Association between obesity-related dyspnea in daily living, lung function and body composition analyzed by DXA: A prospective study of 130 patients. *BMC Pulm Med* 2022;**22**:103. <https://doi.org/10.1186/s12890-022-01884-5>
 66. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al.; BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: A meta-analysis of 21 cohort studies including more than 300 000 persons. *Arch Intern Med* 2007;**167**:1720–1728. <https://doi.org/10.1001/archinte.167.16.1720>
 67. Jamaly S, Carlsson L, Peltonen M, Andersson-Assarsson JC, Karason K. Heart failure development in obesity: Underlying risk factors and mechanistic pathways. *ESC Heart Fail* 2021;**8**:356–367. <https://doi.org/10.1002/ehf2.13081>
 68. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. *Nat Rev Cardiol* 2022;**19**:100–116. <https://doi.org/10.1038/s41569-021-00605-5>
 69. Valente V, Ferrannini G, Benson L, Gatti P, Guidetti F, Melin M, et al. Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: Incidence, prevalence, and treatment strategies. *Eur J Heart Fail* 2025;**27**:236–248. <https://doi.org/10.1002/ehf.3402>
 70. Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. *JACC Heart Fail* 2017;**5**:565–574. <https://doi.org/10.1016/j.jchf.2017.05.001>
 71. Iacobellis G, Ribaudo MC, Leto G, Zappaterreno A, Vecchi E, di Mario U, et al. Influence of excess fat on cardiac morphology and function: Study in uncomplicated obesity. *Obes Res* 2002;**10**:767–773. <https://doi.org/10.1038/oby.2002.104>
 72. Otsuka N, Okumura Y, Arai M, Kurokawa S, Nagashima K, Watanabe R, et al. Effect of obesity and epicardial fat/fatty infiltration on electrical and structural remodeling associated with atrial fibrillation in a novel canine model of obesity and atrial fibrillation: A comparative study. *J Cardiovasc Electrophysiol* 2021;**32**:889–899. <https://doi.org/10.1111/jce.14955>
 73. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JPM, et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as

- consequences of sustained obesity. *J Am Coll Cardiol* 2015;**66**:1–11. <https://doi.org/10.1016/j.jacc.2015.04.058>
74. Liu F, Song T, Hu Q, Zhu X, Zhao H, Tan Z, et al. Body mass index and atrial fibrillation recurrence post ablation: A systematic review and dose-response meta-analysis. *Front Cardiovasc Med* 2022;**9**:999845. <https://doi.org/10.3389/fcvm.2022.999845>
 75. Brachmann J, Sohns C, Andresen D, Siebels J, Sehner S, Boersma L, et al. Atrial fibrillation burden and clinical outcomes in heart failure: The CASTLE-AF trial. *JACC Clin Electrophysiol* 2021;**7**:594–603. <https://doi.org/10.1016/j.jacep.2020.11.021>
 76. Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, et al. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. *Clin Res Cardiol* 2020;**109**:331–338. <https://doi.org/10.1007/s00392-019-01513-y>
 77. Capone F, Sotomayor-Flores C, Bode D, Wang R, Rodolico D, Strocchi S, et al. Cardiac metabolism in HFpEF: From fuel to signalling. *Cardiovasc Res* 2023;**118**:3556–3575. <https://doi.org/10.1093/cvr/cvac166>
 78. Lopuschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. *Circ Res* 2021;**128**:1487–1513. <https://doi.org/10.1161/CIRCRESAHA.121.318241>
 79. Diakos NA, Navakasattusas S, Abel ED, Rutter J, McCreath L, Ferrin P, et al. Evidence of glycolysis up-regulation and pyruvate mitochondrial oxidation mismatch during mechanical unloading of the failing human heart: Implications for cardiac reloading and conditioning. *JACC Basic Transl Sci* 2016;**1**:432–444. <https://doi.org/10.1016/j.jacbs.2016.06.009>
 80. Sun Q, Guven B, Wagg CS, Almeida de Oliveira A, Silver H, Zhang L, et al. Mitochondrial fatty acid oxidation is the major source of cardiac adenosine triphosphate production in heart failure with preserved ejection fraction. *Cardiovasc Res* 2024;**120**:360–371. <https://doi.org/10.1093/cvr/cvae006>
 81. Burrage MK, Hundertmark M, Valkovic L, Watson WD, Rayner J, Sabharwal N, et al. Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction. *Circulation* 2021;**144**:1664–1678. <https://doi.org/10.1161/CIRCULATIONAHA.121.054858>
 82. Ramirez M, Amate L, Gil A. Absorption and distribution of dietary fatty acids from different sources. *Early Hum Dev* 2001;**65**:S95–S101. [https://doi.org/10.1016/s0378-3782\(01\)00211-0](https://doi.org/10.1016/s0378-3782(01)00211-0)
 83. D'Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. *Biochim Biophys Acta* 2016;**1861**:1513–1524. <https://doi.org/10.1016/j.bbalip.2016.02.016>
 84. Gaborit B, Venteclef N, Ancel P, Pelloux V, Gariboldi V, Leprince P, et al. Human epicardial adipose tissue has a specific transcriptomic signature depending on its anatomical peri-atrial, peri-ventricular, or peri-coronary location. *Cardiovasc Res* 2015;**108**:62–73. <https://doi.org/10.1093/cvr/cvv208>
 85. Alam MS, Green R, de Kemp R, Beanlands RS, Chow BJ. Epicardial adipose tissue thickness as a predictor of impaired microvascular function in patients with non-obstructive coronary artery disease. *J Nucl Cardiol* 2013;**20**:804–812. <https://doi.org/10.1007/s12350-013-9739-6>
 86. Salgado-Somoza A, Teixeira-Fernandez E, Fernandez AL, Gonzalez-Juanatey JR, Eiras S. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. *Am J Physiol Heart Circ Physiol* 2010;**299**:H202–H209. <https://doi.org/10.1152/ajpheart.00120.2010>
 87. Doesch C, Haghi D, Fluchter S, Suselbeck T, Schoenberg SO, Michael H, et al. Epicardial adipose tissue in patients with heart failure. *J Cardiovasc Magn Reson* 2010;**12**:40. <https://doi.org/10.1186/1532-429X-12-40>
 88. Fontes-Carvalho R, Fontes-Oliveira M, Sampaio F, Mancio J, Bettencourt N, Teixeira M, et al. Influence of epicardial and visceral fat on left ventricular diastolic and systolic functions in patients after myocardial infarction. *Am J Cardiol* 2014;**114**:1663–1669. <https://doi.org/10.1016/j.amjcard.2014.08.037>
 89. Yang X, Wang X, Liu D, Yu L, Xue B, Shi H. Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b. *Mol Endocrinol* 2014;**28**:565–574. <https://doi.org/10.1210/me.2013-1293>
 90. Shen W, Wang C, Xia L, Fan C, Dong H, Deckelbaum RJ, et al. Epigenetic modification of the leptin promoter in diet-induced obese mice and the effects of N-3 polyunsaturated fatty acids. *Sci Rep* 2014;**4**:5282. <https://doi.org/10.1038/srep05282>
 91. Lewandowski ED, Fischer SK, Fasano M, Banke NH, Walker LA, Huqi A, et al. Acute liver carnitine palmitoyltransferase I overexpression recapitulates reduced palmitate oxidation of cardiac hypertrophy. *Circ Res* 2013;**112**:57–65. <https://doi.org/10.1161/CIRCRESAHA.112.274456>
 92. Carley AN, Maurya SK, Fasano M, Wang Y, Selzman CH, Drakos SG, et al. Short-chain fatty acids outpace ketone oxidation in the failing heart. *Circulation* 2021;**143**:1797–1808. <https://doi.org/10.1161/CIRCULATIONAHA.120.052671>
 93. Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. *Physiol Genomics* 2016;**48**:826–834. <https://doi.org/10.1152/physiolgenomics.00089.2016>
 94. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* 2003;**278**:11312–11319. <https://doi.org/10.1074/jbc.M211609200>
 95. Kaye DM, Shihata WA, Jama HA, Tsygankov K, Ziemann M, Kiriazis H, et al. Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. *Circulation* 2020;**141**:1393–1403. <https://doi.org/10.1161/CIRCULATIONAHA.119.043081>
 96. Olaniyi KS, Owolabi MN, Atuma CL, Agunbiade TB, Alabi BY. Acetate rescues defective brain-adipose metabolic network in obese Wistar rats by modulation of peroxisome proliferator-activated receptor-γ. *Sci Rep* 2021;**11**:18967. <https://doi.org/10.1038/s41598-021-98605-5>
 97. Davie JR. Inhibition of histone deacetylase activity by butyrate. *J Nutr* 2003;**133**:2485S–2493S. <https://doi.org/10.1093/jn/133.7.2485S>
 98. Karwi QG, Zhang L, Altamimi TR, Wagg CS, Patel V, Uddin GM, et al. Weight loss enhances cardiac energy metabolism and function in heart failure associated with obesity. *Diabetes Obes Metab* 2019;**21**:1944–1955. <https://doi.org/10.1111/dom.13762>
 99. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet* 1963;**1**:785–789. [https://doi.org/10.1016/s0140-6736\(63\)91500-9](https://doi.org/10.1016/s0140-6736(63)91500-9)
 100. Matsuura TR, Puchalska P, Crawford PA, Kelly DP. Ketones and the heart: Metabolic principles and therapeutic implications. *Circ Res* 2023;**132**:882–898. <https://doi.org/10.1161/CIRCRESAHA.123.321872>
 101. Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. *JCI Insight* 2019;**4**:e124079. <https://doi.org/10.1172/jci.insight.124079>
 102. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, et al. New nomenclature for chromatin-modifying enzymes. *Cell* 2007;**131**:633–636. <https://doi.org/10.1016/j.cell.2007.10.039>
 103. Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, et al. Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF. *Circ Res* 2021;**128**:232–245. <https://doi.org/10.1161/CIRCRESAHA.120.317933>
 104. Sargsyan N, Chen JY, Aggarwal R, Fadel MG, Fehervari M, Ashrafian H. The effects of bariatric surgery on cardiac function: A systematic review and meta-analysis. *Int J Obes (Lond)* 2024;**48**:166–176. <https://doi.org/10.1038/s41366-023-01412-3>
 105. Anvari S, Lee Y, Lam M, Wong JA, Hong D, Doumouras AG. Effect of bariatric surgery on natriuretic peptide levels: A systematic review and meta-analysis. *Cardiol Rev* 2022;**30**:8–15. <https://doi.org/10.1097/CRD.0000000000000378>
 106. Konishi M, Kagiya N, Kamiya K, Saito H, Saito K, Ogasahara Y, et al. Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. *Eur J Prev Cardiol* 2021;**28**:1022–1029. <https://doi.org/10.1093/eurjpc/zwaa117>
 107. von Haehling S, Garfias Macedo T, Valentova M, Anker MS, Ebner N, Bekfani T, et al. Muscle wasting as an independent predictor of survival in patients with chronic heart failure. *J Cachexia Sarcopenia Muscle* 2020;**11**:1242–1249. <https://doi.org/10.1002/jcsm.12603>
 108. Carrette C, Okamba-Belle D, Hirlemann M, Wack M, Domenge O, Janot AS, et al. Systematic brain natriuretic peptide measurement for cardiac screening in patients with severe obesity: The OLECOEUR study. *Obes Facts* 2024;**17**:296–302. <https://doi.org/10.1159/000538766>
 109. Adams V, Linke A, Winzer E. Skeletal muscle alterations in HFref vs. HFpEF. *Curr Heart Fail Rep* 2017;**14**:489–497. <https://doi.org/10.1007/s11897-017-0361-9>
 110. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2022;**24**:4–131. <https://doi.org/10.1002/ehf.2333>
 111. Lena A, Ebner N, Anker MS. Cardiac cachexia. *Eur Heart J Suppl* 2019;**21**:L24–L27. <https://doi.org/10.1093/eurheartj/suz241>
 112. Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, et al. Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting. *Circulation* 2025;**151**:976–989. <https://doi.org/10.1161/CIRCULATIONAHA.124.072156>
 113. Antoniadou C, Tousoulis D, Vavliakis M, Fleming I, Duncker DJ, Eringa E, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. *Eur Heart J* 2023;**44**:3827–3844. <https://doi.org/10.1093/eurheartj/ehad484>

114. Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. *Circ Res* 2021;**128**:136–149. <https://doi.org/10.1161/CIRCRESAHA.120.314458>
115. Packer M. Leptin-aldosterone-nephrilysin axis: Identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. *Circulation* 2018;**137**:1614–1631. <https://doi.org/10.1161/CIRCULATIONAHA.117.032474>
116. van der Hoef CCS, Boersma EM, Emmens JE, van Essen BJ, Metra M, Ng LL, et al. Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome. *Eur J Heart Fail* 2023;**25**:163–173. <https://doi.org/10.1002/ehf.2760>
117. Mado H, Szczurek W, Gąsior M, Szyguła-Jurkiewicz B. Adiponectin in heart failure. *Future Cardiol* 2021;**17**:757–764. <https://doi.org/10.2217/fca-2020-0095>
118. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. *Circulation* 2005;**112**:1756–1762. <https://doi.org/10.1161/CIRCULATIONAHA.104.530972>
119. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. *FEBS J* 2020;**287**:3141–3149. <https://doi.org/10.1111/febs.15322>
120. Bobbert P, Jenke A, Bobbert T, Kühl U, Rauch U, Lassner D, et al. High leptin and resistin expression in chronic heart failure: Adverse outcome in patients with dilated and inflammatory cardiomyopathy. *Eur J Heart Fail* 2012;**14**:1265–1275. <https://doi.org/10.1093/eurjhf/hfs111>
121. Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. *Heart Fail Rev* 2023;**28**:261–272. <https://doi.org/10.1007/s10741-022-10268-0>
122. Zhang X, Yeung DC, Karpisek M, Yeung DCY, Stejskal D, Zhou Z-G, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. *Diabetes* 2008;**57**:1246–1253. <https://doi.org/10.2337/db07-1476>
123. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. *Diabetes* 2010;**59**:2781–2789. <https://doi.org/10.2337/db10-0193>
124. Zhang Y, Yan J, Yang N, Qian Z, Nie H, Yang Z, et al. High-level serum fibroblast growth factor 21 concentration is closely associated with an increased risk of cardiovascular diseases: A systematic review and meta-analysis. *Front Cardiovasc Med* 2021;**8**:705273. <https://doi.org/10.3389/fcvm.2021.705273>
125. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Klierer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. *Diabetes* 2014;**63**:4057–4063. <https://doi.org/10.2337/db14-0595>
126. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. *Clin Chem* 2017;**63**:140–151. <https://doi.org/10.1373/clinchem.2016.255174>
127. Teramoto K, Nochioka K, Sakata Y, Kato ET, Nishimura K, Shimokawa H, et al; SUPPORT Trial Investigators. Growth differentiation factor-15 and metabolic features in chronic heart failure: Insights from the SUPPORT trial-GDF15 across the BMI spectrum. *Int J Cardiol* 2024;**407**:132093. <https://doi.org/10.1016/j.ijcard.2024.132093>
128. Alogna A, Koepp KE, Sabbah M, Espindola Netto JM, Jensen MD, Kirkland JL, et al. Interleukin-6 in patients with heart failure and preserved ejection fraction. *JACC Heart Fail* 2023;**11**:1549–1561. <https://doi.org/10.1016/j.jchf.2023.06.031>
129. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. *JAMA* 2006;**295**:1412–1419. <https://doi.org/10.1001/jama.295.12.1412>
130. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 1999;**282**:2131–2135. <https://doi.org/10.1001/jama.282.22.2131>
131. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: A systematic review. *Arch Intern Med* 2007;**167**:31–39. <https://doi.org/10.1001/archinte.167.1.31>
132. Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. *EClinicalMedicine* 2023;**55**:101737. <https://doi.org/10.1016/j.eclinm.2022.101737>
133. Larsson SC, Back M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: A Mendelian randomization study. *Eur Heart J* 2020;**41**:221–226. <https://doi.org/10.1093/eurheartj/ehz388>
134. Thomas E, Gupta PP, Fonarow GC, Horwich TB. Bioelectrical impedance analysis of body composition and survival in patients with heart failure. *Clin Cardiol* 2019;**42**:129–135. <https://doi.org/10.1002/clc.23118>
135. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. *Eur Heart J* 1999;**20**:683–693. <https://doi.org/10.1053/ehj.1998.1446>
136. Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. *Eur J Heart Fail* 2020;**22**:1540–1550. <https://doi.org/10.1002/ehf.1956>
137. Selvaraj S, Kim J, Ansari BA, Zhao L, Cvijic ME, Fronheiser M, et al. Body composition, natriuretic peptides, and adverse outcomes in heart failure with preserved and reduced ejection fraction. *JACC Cardiovasc Imaging* 2021;**14**:203–215. <https://doi.org/10.1016/j.jcmg.2020.07.022>
138. Rao VN, Zhao D, Allison MA, Gualler E, Sharma K, Criqui MH, et al. Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). *JACC Heart Fail* 2018;**6**:999–1007. <https://doi.org/10.1016/j.jchf.2018.07.009>
139. Li X, Zhang N, Hu C, Lin Y, Li J, Li Z, et al. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study. *EClinicalMedicine* 2023;**56**:101805. <https://doi.org/10.1016/j.eclinm.2022.101805>
140. Singh M, Sethi A, Mishra AK, Subrayappa NK, Stapleton DD, Pellikka PA. Echocardiographic imaging challenges in obesity: Guideline recommendations and limitations of adjusting to body size. *J Am Heart Assoc* 2020;**9**:e014609. <https://doi.org/10.1161/JAHA.119.014609>
141. van Woerden G, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. *Eur J Heart Fail* 2018;**20**:1559–1566. <https://doi.org/10.1002/ehf.1283>
142. Venkateshvaran A, Faxen UL, Hage C, Michaëlsson E, Svedlund S, Saraste A, et al. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: Insights from the PROMIS-HFpEF study. *Eur J Heart Fail* 2022;**24**:2251–2260. <https://doi.org/10.1002/ehf.2709>
143. Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. *JACC Heart Fail* 2020;**8**:657–666. <https://doi.org/10.1016/j.jchf.2020.04.016>
144. Tromp J, Bryant JA, Jin X, van Woerden G, Asali S, Yiyiing H, et al. Epicardial fat in heart failure with reduced versus preserved ejection fraction. *Eur J Heart Fail* 2021;**23**:835–838. <https://doi.org/10.1002/ehf.2156>
145. Tromp J, Packer M, Lam CS. The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: Not all fat is created equal. *Eur J Heart Fail* 2021;**23**:1872–1874. <https://doi.org/10.1002/ehf.2363>
146. Aitken-Buck HM, Moharram M, Babakr AA, Reijers R, van Hout I, Fomison-Nurse IC, et al. Relationship between epicardial adipose tissue thickness and epicardial adipocyte size with increasing body mass index. *Adipocyte* 2019;**8**:412–420. <https://doi.org/10.1080/21623945.2019.1701387>
147. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. *Nat Rev Cardiol* 2022;**19**:593–606. <https://doi.org/10.1038/s41569-022-00679-9>
148. Ge Y, Steel K, Antiochos P, Bingham S, Abdullah S, Mikolich JR, et al. Stress CMR in patients with obesity: Insights from the Stress CMR Perfusion Imaging in the United States (SPINS) registry. *Eur Heart J Cardiovasc Imaging* 2021;**22**:518–527. <https://doi.org/10.1093/ehjci/jeaa281>
149. Szabo L, McCracken C, Cooper J, Rider OJ, Vago H, Merkely B, et al. The role of obesity-related cardiovascular remodelling in mediating incident cardiovascular outcomes: A population-based observational study. *Eur Heart J Cardiovasc Imaging* 2023;**24**:921–929. <https://doi.org/10.1093/ehjci/jeac270>
150. Beitler JR, Awad KM, Bakker JP, Edwards BA, DeYoung P, Djonlagic I, et al. Obstructive sleep apnea is associated with impaired exercise capacity: A cross-sectional study. *J Clin Sleep Med* 2014;**10**:1199–1204. <https://doi.org/10.5664/jcsm.4200>
151. O'Connor E, Green S, Kiely C, O'Shea D, Egana M. Differential effects of age and type 2 diabetes on dynamic vs. peak response of pulmonary oxygen uptake during exercise. *J Appl Physiol* 2015;**118**:1031–1039. <https://doi.org/10.1152/japplphysiol.01040.2014>
152. Nevill AM, Ramsbottom R, Williams C. Scaling physiological measurements for individuals of different body size. *Eur J Appl Physiol Occup Physiol* 1992;**65**:110–117. <https://doi.org/10.1007/BF00705066>
153. Vanderburgh PM, Katch FI. Ratio scaling of $\dot{V}O_{2\max}$ penalizes women with larger percent body fat, not lean body mass. *Med Sci Sports Exerc* 1996;**28**:1204–1208. <https://doi.org/10.1097/00005768-199609000-00019>
154. Corrà U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018;**20**:3–15. <https://doi.org/10.1002/ehf.979>

155. Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A, et al. Complex interaction of obesity, intentional weight loss and heart failure: A systematic review and meta-analysis. *Heart* 2020;**106**:58–68. <https://doi.org/10.1136/heartjnl-2019-314770>
156. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: A prespecified analysis of the STEP-HFpEF trial. *Nat Med* 2023;**29**:2358–2365. <https://doi.org/10.1038/s41591-023-02526-x>
157. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023;**389**:2221–2232. <https://doi.org/10.1056/NEJMoa2307563>
158. Neeland IJ, McGuire DK, Sattar N. Cardiovascular outcomes trials for weight loss interventions: Another tool for cardiovascular prevention? *Circulation* 2021;**144**:1359–1361. <https://doi.org/10.1161/CIRCULATIONAHA.121.056742>
159. Chi M, Nie Y, Su Y, Wang N, Li A, Ma T, et al. Effects of weight loss in heart failure patients with overweight and obesity: A systematic review and meta-analysis. *Eur J Prev Cardiol* 2023;**30**:1906–1921. <https://doi.org/10.1093/eurjpc/zwad284>
160. Takaoka M, Tadross JA, Al-Hadithi ABAK, Zhao X, Villena-Gutiérrez R, Tromp J, et al. GDF15 antagonism limits severe heart failure and prevents cardiac cachexia. *Cardiovasc Res* 2024;**120**:2249–2260. <https://doi.org/10.1093/cvr/cvae214>
161. Lena A, Coats AJS, Anker MS. Metabolic disorders in heart failure and cancer. *ESC Heart Fail* 2018;**5**:1092–1098. <https://doi.org/10.1002/ehf2.12389>
162. Alvarez P, Hannawi B, Guha A. Exercise and heart failure: Advancing knowledge and improving care. *Methodist Debaque Cardiovasc J* 2016;**12**:110–115. <https://doi.org/10.14797/mdcj-12-2-110>
163. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: An Endocrine Society scientific statement. *Endocr Rev* 2018;**39**:79–132. <https://doi.org/10.1210/er.2017-00253>
164. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al.; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. *Circulation* 2021;**143**:e984–e1010. <https://doi.org/10.1161/CIR.0000000000000973>
165. Peck KH, Dulay MS, Hameed S, Rosano G, Tan T, Dar O. Intentional weight loss in overweight and obese patients with heart failure: A systematic review. *Eur J Heart Fail* 2024;**26**:1907–1930. <https://doi.org/10.1002/ehf2.3270>
166. Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, et al. Nutrition, obesity, and cachexia in patients with heart failure: A consensus statement from the Heart Failure Society of America Scientific Statements Committee. *J Card Fail* 2019;**25**:380–400. <https://doi.org/10.1016/j.cardfail.2019.03.007>
167. Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of orlistat in obese patients with heart failure: A pilot study. *Congest Heart Fail* 2005;**11**:118–123. <https://doi.org/10.1111/j.1527-5299.2005.03827.x>
168. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2023;**389**:1069–1084. <https://doi.org/10.1056/NEJMoa2306963>
169. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al.; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. *N Engl J Med* 2024;**390**:1394–1407. <https://doi.org/10.1056/NEJMoa2313917>
170. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2025;**392**:427–437. <https://doi.org/10.1056/NEJMoa2410027>
171. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial. *JAMA* 2016;**315**:36–46. <https://doi.org/10.1001/jama.2015.17346>
172. Evangelista LS, Heber D, Li Z, Bowerman S, Hamilton MA, Fonarow GC. Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: A feasibility study. *J Cardiovasc Nurs* 2009;**24**:207–215. <https://doi.org/10.1097/JCN.0b013e31819846b9>
173. Evangelista LS, Doering LV, Lennie T, Moser DK, Hamilton MA, Fonarow GC, et al. Usefulness of a home-based exercise program for overweight and obese patients with advanced heart failure. *Am J Cardiol* 2006;**97**:886–890. <https://doi.org/10.1016/j.amjcard.2005.10.025>
174. Gonzalez-Islas D, Orea-Tejeda A, Castillo-Martinez L, Olvera-Mayorga G, Rodriguez-Garcia WD, Santillan-Diaz C, et al. The effects of a low-carbohydrate diet on oxygen saturation in heart failure patients: A randomized controlled clinical trial. *Nutr Hosp* 2017;**34**:792–798. <https://doi.org/10.20960/nh.784>
175. Evangelista LS, Jose MM, Sallam H, Serag H, Golovko G, Khanipov K, et al. High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: Findings of the Pro-HEART trial. *ESC Heart Fail* 2021;**8**:1342–1348. <https://doi.org/10.1002/ehf2.13213>
176. Brubaker PH, Nicklas BJ, Houston DK, Hundley WG, Chen H, Molina AJA, et al. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. *Circ Heart Fail* 2023;**16**:e010161. <https://doi.org/10.1161/CIRCHEARTFAILURE.122.010161>
177. Pritchett AM, Deswal A, Aguilar D, Foreyt JP, Chan W, Mann DL, et al. Lifestyle modification with diet and exercise in obese patients with heart failure – a pilot study. *J Obes Weight Loss Ther* 2012;**2**:1–8. <https://doi.org/10.4172/2165-7904.1000118>
178. Yost G, Coyle L, Gallagher C, Graney N, Siemcek R, Tatoes A, et al. The impact of extreme obesity on outcomes after left ventricular assist device implantation. *J Thorac Dis* 2017;**9**:4441–4446. <https://doi.org/10.21037/jtd.2017.10.52>
179. Singh S, Takeda K, Kurlansky P. The impact of obesity on outcomes after left ventricular assist device implantation: Time to settle the debate. *Eur J Cardiothorac Surg* 2022;**62**:ezac425. <https://doi.org/10.1093/ejcts/ezac425>
180. Jaiswal A, Truby LK, Chichra A, Jain R, Myers L, Patel N, et al. Impact of obesity on ventricular assist device outcomes. *J Card Fail* 2020;**26**:287–297. <https://doi.org/10.1016/j.cardfail.2019.10.001>
181. Clerkin KJ, Naka Y, Mancini DM, Colombo PC, Topkara VK. The impact of obesity on patients bridged to transplantation with continuous-flow left ventricular assist devices. *JACC Heart Fail* 2016;**4**:761–768. <https://doi.org/10.1016/j.jchf.2016.05.010>
182. Russo MJ, Hong KN, Davies RR, Chen JM, Mancini DM, Oz MC, et al. The effect of body mass index on survival following heart transplantation: Do outcomes support consensus guidelines? *Ann Surg* 2010;**251**:144–152. <https://doi.org/10.1097/SLA.0b013e3181b5db3c>
183. Myers J, Prakash M, Froelicher V, do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. *N Engl J Med* 2002;**346**:793–801. <https://doi.org/10.1056/NEJMoa011858>
184. Horwich TB, Broderick S, Chen L, McCullough PA, Strzelczyk T, Kitzman DW, et al. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. *Am J Cardiol* 2011;**108**:1754–1759. <https://doi.org/10.1016/j.amjcard.2011.07.051>
185. Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. *N Engl J Med* 2021;**385**:203–216. <https://doi.org/10.1056/NEJMoa2061411>
186. Leggio M, Fusco A, Loreti C, Limongelli G, Bendini MG, Mazza A, et al. Effects of exercise training in heart failure with preserved ejection fraction: An updated systematic literature review. *Heart Fail Rev* 2020;**25**:703–711. <https://doi.org/10.1007/s10741-019-09841-x>
187. Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. *Heart Fail Rev* 2019;**24**:535–547. <https://doi.org/10.1007/s10741-019-09774-5>
188. Gomes-Neto M, Duraes AR, Conceicao LSR, Roevers L, Liu T, Tse G, et al. Effect of aerobic exercise on peak oxygen consumption, VE/VCO₂ slope, and health-related quality of life in patients with heart failure with preserved left ventricular ejection fraction: A systematic review and meta-analysis. *Curr Atheroscler Rep* 2019;**21**:45. <https://doi.org/10.1007/s11883-019-0806-6>
189. Sachdev V, Sharma K, Keteyian SJ, Alcaín CF, Desvigne-Nickens P, Fleg JL, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and American College of Cardiology. Supervised exercise training for chronic heart failure with preserved ejection fraction: A scientific statement from the American Heart Association and American College of Cardiology. *Circulation* 2023;**147**:e699–e715. <https://doi.org/10.1161/CIR.0000000000001122>
190. Cruzen C, Colman RJ. Effects of caloric restriction on cardiovascular aging in non-human primates and humans. *Clin Geriatr Med* 2009;**25**:733–743. <https://doi.org/10.1016/j.cger.2009.07.001>
191. Kraus WE, Bhapkar M, Huffman KM, Pieper CF, Krupa das S, Redman LM, et al.; CALERIE Investigators. 2 years of calorie restriction and cardiometabolic risk (CALERIE): Exploratory outcomes of a multicentre, phase 2, randomised controlled trial. *Lancet Diabetes Endocrinol* 2019;**7**:673–683. [https://doi.org/10.1016/S2213-8587\(19\)30151-2](https://doi.org/10.1016/S2213-8587(19)30151-2)

192. Ayinapudi K, Samson R, Le Jemtel TH, Marrouche NF, Oparil S. Weight reduction for obesity-induced heart failure with preserved ejection fraction. *Curr Hypertens Rep* 2020;**22**:47. <https://doi.org/10.1007/s11906-020-01074-w>
193. Ard JD, Gower B, Hunter G, Ritchie CS, Roth DL, Goss A, et al. Effects of calorie restriction in obese older adults: The CROSSROADS randomized controlled trial. *J Gerontol A Biol Sci Med Sci* 2017;**73**:73–80. <https://doi.org/10.1093/gerona/glw237>
194. Cardoso CRL, Leite NC, Salles GF. Effects of weight loss and interaction with physical activity on risks of cardiovascular outcomes in individuals with type 2 diabetes. *Endocrinol Metab (Seoul)* 2023;**38**:305–314. <https://doi.org/10.3803/EnM.2023.1690>
195. Look AHEAD Research Group; Wing RR, Bolin P, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013;**369**:145–154. <https://doi.org/10.1056/NEJMoa1212914>
196. Liu M, Huang R, Xu L, Zhang S, Zhong X, Chen X, et al. Cardiovascular effects of intensive lifestyle intervention in adults with overweight/obesity and type 2 diabetes according to body weight time in range. *EclinicalMedicine* 2022;**49**:101451. <https://doi.org/10.1016/j.eclim.2022.101451>
197. El Hajj EC, El Hajj MC, Sykes B, Lamicq M, Zile MR, Malcolm R, et al. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. *J Am Heart Assoc* 2021;**10**:e022930. <https://doi.org/10.1161/JAHA.121.022930>
198. Takahara S, Soni S, Maayah ZH, Ferdaoussi M, Dyck JRB. Ketone therapy for heart failure: Current evidence for clinical use. *Cardiovasc Res* 2022;**118**:977–987. <https://doi.org/10.1093/cvr/cvab068>
199. Khan MS, Khan F, Fonarow GC, Sreenivasan J, Greene SJ, Khan SU, et al. Dietary interventions and nutritional supplements for heart failure: A systematic appraisal and evidence map. *Eur J Heart Fail* 2021;**23**:1468–1476. <https://doi.org/10.1002/ehf.2278>
200. Seidemann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, et al. Dietary carbohydrate intake and mortality: A prospective cohort study and meta-analysis. *Lancet Public Health* 2018;**3**:e419–e428. [https://doi.org/10.1016/S2468-2667\(18\)30135-X](https://doi.org/10.1016/S2468-2667(18)30135-X)
201. Kodur N, Yurista S, Province V, Rueth E, Nguyen C, Tang WHW. Ketogenic diet in heart failure: Fact or fiction? *JACC Heart Fail* 2023;**11**:838–844. <https://doi.org/10.1016/j.jchf.2023.05.009>
202. James WP, Caterson ID, Coutinho W, Finer N, van Gaal L, Maggioni AP, et al. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med* 2010;**363**:905–917. <https://doi.org/10.1056/NEJMoa1003114>
203. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. *N Engl J Med* 2012;**367**:1577–1579. <https://doi.org/10.1056/NEJMp1211277>
204. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttauria M, Erickson J, et al.; COR-1 Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2010;**376**:595–605. [https://doi.org/10.1016/S0140-6736\(10\)60888-4](https://doi.org/10.1016/S0140-6736(10)60888-4)
205. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. *Lancet* 2022;**400**:757–767. [https://doi.org/10.1016/S0140-6736\(22\)01429-5](https://doi.org/10.1016/S0140-6736(22)01429-5)
206. Adamson C, Jhund PS, Docherty KF, Bělohávek J, Chiang CE, Diez M, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. *Eur J Heart Fail* 2021;**23**:1662–1672. <https://doi.org/10.1002/ehf.2308>
207. Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B, et al. Dapagliflozin for heart failure according to body mass index: The DELIVER trial. *Eur Heart J* 2022;**43**:4406–4417. <https://doi.org/10.1093/eurheartj/ehac481>
208. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. *Drugs* 2019;**79**:219–230. <https://doi.org/10.1007/s40265-019-1057-0>
209. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. *Diabetes Obes Metab* 2016;**18**:783–794. <https://doi.org/10.1111/dom.12670>
210. Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: A meta-analysis of randomized controlled trials for 1 to 2 years. *J Diabetes Complications* 2015;**29**:1295–1303. <https://doi.org/10.1016/j.jdiacomp.2015.07.011>
211. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016;**375**:1834–1844. <https://doi.org/10.1056/NEJMoa1607141>
212. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;**375**:311–322. <https://doi.org/10.1056/NEJMoa1603827>
213. Wilding JPH, Batterham RL, Calanna S, Davies M, van Gaal LF, Lingvay I, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med* 2021;**384**:989–1002. <https://doi.org/10.1056/NEJMoa2032183>
214. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med* 2015;**373**:11–22. <https://doi.org/10.1056/NEJMoa1411892>
215. Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. *J Clin Endocrinol Metab* 2020;**105**:1552–1563. <https://doi.org/10.1210/clinem/dgz140>
216. Vezza T, Victor VM. Beyond weight loss: Evaluating cardiovascular advantages of GLP-1 receptor agonists. *Am J Cardiovasc Drugs* 2024;**24**:505–507. <https://doi.org/10.1007/s40256-024-00650-8>
217. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action. *Nat Rev Cardiol* 2023;**20**:463–474. <https://doi.org/10.1038/s41569-023-00849-3>
218. de Oliveira Almeida G, Nienkotter TF, Balieiro CCA, Pasqualotto E, Cintra JB, Carvalho HCP, et al. Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: A meta-analysis of randomized controlled trials. *Am J Cardiovasc Drugs* 2024;**24**:509–521. <https://doi.org/10.1007/s40256-024-00647-3>
219. Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, et al.; STEP-HFpEF Trial Committees and Investigators. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. *J Am Coll Cardiol* 2024;**84**:1587–1602. <https://doi.org/10.1016/j.jacc.2024.08.021>
220. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al.; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. *Lancet* 2024;**404**:949–961. [https://doi.org/10.1016/S0140-6736\(24\)01643-X](https://doi.org/10.1016/S0140-6736(24)01643-X)
221. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med* 2022;**387**:205–216. <https://doi.org/10.1056/NEJMoa2206038>
222. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial. *Nat Med* 2025;**31**:544–551. <https://doi.org/10.1038/s41591-024-03374-z>
223. Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria J, Menon V, et al.; SUMMIT Trial Study Group. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. *J Am Coll Cardiol* 2025;**85**:699–706. <https://doi.org/10.1016/j.jacc.2024.11.001>
224. Karakakis P, Patoulas D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. *Metabolism* 2025;**164**:156113. <https://doi.org/10.1016/j.metabol.2024.156113>
225. Linde J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: Adaptive or maladaptive response to weight loss? *Circulation* 2024;**150**:1288–1298. <https://doi.org/10.1161/CIRCULATIONAHA.124.067676>
226. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al.; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. *JAMA* 2016;**316**:500–508. <https://doi.org/10.1001/jama.2016.10260>
227. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo-controlled trial. *Eur J Heart Fail* 2017;**19**:69–77. <https://doi.org/10.1002/ehf.657>
228. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial. *Lancet* 2024;**404**:773–786. [https://doi.org/10.1016/S0140-6736\(24\)01498-3](https://doi.org/10.1016/S0140-6736(24)01498-3)
229. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. *Diabetes Res Clin Pract* 2015;**110**:26–37. <https://doi.org/10.1016/j.diabres.2015.07.015>

230. Hage C. GLP-1 receptor agonists in heart failure: How far to expand use? *Lancet* 2024;**404**:909–911. [https://doi.org/10.1016/S0140-6736\(24\)01763-X](https://doi.org/10.1016/S0140-6736(24)01763-X)
231. Schiavon CA, Cavalcanti AB, Oliveira JD, Machado RHV, Santucci EV, Santos RN, et al. Randomized trial of effect of bariatric surgery on blood pressure after 5 years. *J Am Coll Cardiol* 2024;**83**:637–648. <https://doi.org/10.1016/j.jacc.2023.11.032>
232. Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, et al. Effects of bariatric surgery in obese patients with hypertension: The GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients with Steady Hypertension). *Circulation* 2018;**137**:1132–1142. <https://doi.org/10.1161/CIRCULATIONAHA.117.032130>
233. Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: A population-based retrospective cohort study. *Circulation* 2021;**143**:1468–1480. <https://doi.org/10.1161/CIRCULATIONAHA.120.052386>
234. Hoskuldssdottir G, Sattar N, Miftaraj M, Naslund I, Ottosson J, Franzen S, et al. Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: A nationwide, matched, observational cohort study. *J Am Heart Assoc* 2021;**10**:e019323. <https://doi.org/10.1161/JAHA.120.019323>
235. Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR, et al. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. *J Am Heart Assoc* 2017;**6**:e005126. <https://doi.org/10.1161/JAHA.116.005126>
236. Han H, Zhu T, Guo Y, Ruan Y, Herzog E, He J. Impact of prior bariatric surgery on outcomes of hospitalized patients with heart failure: A population-based study. *Surg Obes Relat Dis* 2019;**15**:469–477. <https://doi.org/10.1016/j.soard.2018.12.030>
237. Aleassa EM, Khorgami Z, Kindel TL, Tu C, Tang WHW, Schauer PR, et al. Impact of bariatric surgery on heart failure mortality. *Surg Obes Relat Dis* 2019;**15**:1189–1196. <https://doi.org/10.1016/j.soard.2019.03.021>
238. Mikhalkova D, Holman SR, Jiang H, Saghir M, Novak E, Coggan AR, et al. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. *Obesity (Silver Spring)* 2018;**26**:284–290. <https://doi.org/10.1002/oby.22038>
239. Shimada YJ, Tsugawa Y, Brown DFM, Hasegawa K. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: Population-based, self-controlled series. *J Am Coll Cardiol* 2016;**67**:895–903. <https://doi.org/10.1016/j.jacc.2015.12.016>
240. Miranda WR, Batsis JA, Sarr MG, Collazo-Clavell ML, Clark MM, Somers VK, et al. Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure. *Obes Surg* 2013;**23**:1011–1015. <https://doi.org/10.1007/s11695-013-0953-8>
241. Reddy YNV, Anantha-Narayanan M, Obokata M, Koepf KE, Erwin P, Carter RE, et al. Hemodynamic effects of weight loss in obesity: A systematic review and meta-analysis. *JACC Heart Fail* 2019;**7**:678–687. <https://doi.org/10.1016/j.jchf.2019.04.019>
242. van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, et al. Bariatric surgery and cardiovascular disease: A systematic review and meta-analysis. *Eur Heart J* 2022;**43**:1955–1969. <https://doi.org/10.1093/eurheartj/ehac071>
243. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. *Cochrane Database Syst Rev* 2014;**2014**:CD003641. <https://doi.org/10.1002/14651858.CD003641.pub4>
244. Stenberg E, Cao Y, Jernberg T, Näsund E. Safety of bariatric surgery in patients with previous acute coronary events or heart failure: Nationwide cohort study. *BJS Open* 2022;**6**:zrac083. <https://doi.org/10.1093/bjsopen/zrac083>
245. Blumer V, Greene SJ, Ortiz M, Kittipibul V, Hernandez GA, Fudim M, et al. In-hospital outcomes after bariatric surgery in patients with heart failure. *Am Heart J* 2020;**230**:59–62. <https://doi.org/10.1016/j.ahj.2020.09.007>
246. Carbone S, Lavie CJ, Arena R. Obesity and heart failure: Focus on the obesity paradox. *Mayo Clin Proc* 2017;**92**:266–279. <https://doi.org/10.1016/j.mayocp.2016.11.001>
247. Olivier A, Pitt B, Giererd N, Lamiral Z, Machu J-L, McMurray JJV, et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: Potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. *Eur J Heart Fail* 2017;**19**:1186–1197. <https://doi.org/10.1002/ehf.792>
248. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2022;**79**:e263–e421. <https://doi.org/10.1016/j.jacc.2021.12.012>
249. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2024;**26**:5–17. <https://doi.org/10.1002/ehf.3024>
250. Smit C, De Hoogd S, Bruggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: A review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. *Expert Opin Drug Metab Toxicol* 2018;**14**:275–285. <https://doi.org/10.1080/17425255.2018.1440287>
251. van der Heijden C, Ter Horst R, van den Munckhof ICL, van der Heijden CDCC, Schraa K, de Graaf J, et al. Vasculometabolic and inflammatory effects of aldosterone in obesity. *J Clin Endocrinol Metab* 2020;**105**:2719–2731. <https://doi.org/10.1210/clinem.dgaa356>
252. Sharma AM, Engeli S. Obesity and the renin-angiotensin-aldosterone system. *Expert Rev Endocrinol Metab* 2006;**1**:255–264. <https://doi.org/10.1586/17446651.1.2.255>
253. Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. *Curr Hypertens Rep* 2012;**14**:160–169. <https://doi.org/10.1007/s11906-012-0245-z>
254. Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. *Am J Cardiol* 2021;**146**:36–47. <https://doi.org/10.1016/j.amjcard.2021.01.018>
255. Gouju J, Legeay S. Pharmacokinetics of obese adults: Not only an increase in weight. *Biomed Pharmacother* 2023;**166**:115281. <https://doi.org/10.1016/j.biopha.2023.115281>
256. Brunner-La Rocca HP, Linszen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH, et al.; CHECK-HF Investigators. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: The CHECK-HF registry. *JACC Heart Fail* 2019;**7**:13–21. <https://doi.org/10.1016/j.jchf.2018.10.010>
257. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study. *Eur Heart J* 2017;**38**:1883–1890. <https://doi.org/10.1093/eurheartj/ehx026>
258. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al.; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2024;**391**:1475–1485. <https://doi.org/10.1056/NEJMoa2407107>
259. Butt JH, McMurray JJ, Claggett BL, McMurray JJV, Jhund PS, Neuen BL, et al. Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: Comprehensive individual participant-level analysis of 6 randomized clinical trials. *Circulation* 2024;**150**:1858–1868. <https://doi.org/10.1161/CIRCULATIONAHA.124.071110>
260. Yang M, Kondo T, Adamson C, Butt JH, Abraham WT, Desai AS, et al. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. *Eur J Heart Fail* 2023;**25**:1606–1618. <https://doi.org/10.1002/ehf.2962>
261. Lindberg F, Lund LH, Benson L, Dahlström U, Karlström P, Linde C, et al. Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: Data from the Swedish Heart Failure Registry. *Eur J Heart Fail* 2022;**24**:2093–2104. <https://doi.org/10.1002/ehf.2644>
262. Greene SJ, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. *JAMA Cardiol* 2021;**6**:522–531. <https://doi.org/10.1001/jamacardio.2021.0372>
263. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, et al. Monitoring clinical changes in patients with heart failure: A comparison of methods. *Am Heart J* 2005;**150**:707–715. <https://doi.org/10.1016/j.ahj.2004.12.010>
264. Lim U, Ernst T, Buchthal SD, Latch M, Albright CL, Wilkens LR, et al. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. *Nutr Diabetes* 2011;**1**:e6. <https://doi.org/10.1038/nutd.2011.2>